

## 2007 Report



# Index

<b>Executive Summary</b>	<b>5</b>
1. Introduction	6
2. Situation and temperature of the spanish biotech sector	7
2.1. Situation of the Sector in Spain	7
2.2. Sector Temperature	7
3. New enterprises	7
4. Business activities undertaken	10
5. Strategic priorities	13
6. Industrial property and knowledge generation	14
7. Red biotechnology	19
8. Green biotechnology	19
9. White biotechnology	19
10. The financial environment	20
11. The social environment (citizens' consensus debate on advanced therapies)	23
<b>Who is Who?</b>	<b>25</b>
Business Members	26
Public Members	78

Edited by Spanish Association of Bioenterprises (ASEBIO)

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopies, recordings or any information storage and retrieval, without written permission from the copyright holders.

© ASEBIO

1st edition: June 2008

Design: Margen


Photocomposition and impression: Ibergráficas, S.A.

Legal deposit:






## Executive Summary







## 1. INTRODUCTION

According to the Survey on Technological Innovation in Companies undertaken by the Spanish National Statistics Bureau (Spanish initials INE), in 2006, 659 enterprises were performing activities related to biotechnology in Spain. This represents an increase of over 38% with respect to 2005, and likewise in that year, practically 90% of those companies had fewer than 250 employees on their payroll. Another significant figure that illustrates the knowledge intensity in the domestic sector, is that some 70% of those firms undertook R&D work during the period under assessment.

## 2. SITUATION AND TEMPERATURE OF THE SPANISH BIOTECH SECTOR

### 2.1. Situation of the Sector in Spain

The turnover of these 659 companies exceeded €2,500 million and they employed over 88,100 people; both variables show growth of over 10%. Internal investment in biotech R&D grew by 46% to approach the €00 million figure.

The Madrid Region, Catalonia, Andalusia and the Basque Country are the Autonomous Communities which recorded the highest numbers of companies fully devoted or which carry out activities to do with biotechnology, as well as being the regions with the highest investments in R&D.

Graph 2.1 shows the spread of companies according to the area in which biotechnology is eventually used. It should be underlined that 40% of the companies focus their activity on Human Health Care while 38% focus on Food.


### 2.2. Sector Temperature

The ASEBIO index, the instrument which has annually measured “temperature” of the sector since the year 2000, reported positive values for the third consecutive year, reflecting an optimistic outlook regarding Spain’s biotech development possibilities. In 2007, moreover, the index achieved its second highest figure, correcting the downward trend shown in 2006.

The most highly valued strengths included: Co-operation with customers and suppliers, improvement of the financial environments and changes in regulations affecting the sector.



As far as barriers are concerned, emphasis was placed on internationalisation, financing and orientation of the technological offering, but in all cases results show they were less intense than in 2006.

**Graph 2.1.** Percentage of companies according to the area in which biotechnology is eventually used  
*Source: Spanish National Statistics Bureau, Survey on Technological Innovation in Companies, 2006*



## 3. NEW ENTERPRISES

Seventy-five new companies fully devoted to biotechnology kicked off their activities during 2007. Catalonia with 27% of these initiatives and Andalusia (20%) led the biotech enterprise creation table for the second year running, ahead of the Madrid Region, the Basque Country and the Valencia Region. Galicia and Castilla León are worthy of mention as new entries among the regions with most entrepreneurial activity, each with 4 new projects, accounting for 5% of the overall figure.





**Table 3.1.** Companies devoted to biotechnology that started up in 2007. *Source: ASEBIO*

Name	Activity	Aut. Community
Thrombotargets Pharma	Research and Development	Catalonia
Thrombotargets Development	Biotech Pilot Plant (GMP)	Madrid
Biotech Libraries	HTS Centre and screening libraries	Catalonia
Chimera	Biopharmaceuticals	Madrid
Fenix Biotech	Gene therapy	Euskadi
Ferrer Incode	Personalised medicine	Catalonia
IMASD	Regenerative medicine	Galicia
Ojer Farma	Dermatology	Navarre
Inn Flavour	Molecular Gastronomy	Catalonia
Endor nanotech	Drug delivery	Catalonia
Bioderivados proteicos	Collagen derivatives	Catalonia
Farmbiocontrol	Biological control	Aragon
Tetra Therapeutics	Personalised medicine	Canary Isles
Camaron de Galicia	Aquaculture	Galicia
Acuiperc	Aquaculture	Galicia
Insecta	Biological control	Andalusia
Microgaia	Biological control	Castilla-La Mancha
Aquasolutions biotech	Aquaculture	Andalusia
Biogolden	Food	Andalusia
Halotech	Diagnosis	Madrid
ClaveSuan	Biopharmaceuticals	Navarre
Bioiliberis	Bioremediation	Andalusia
Bioteco	Aquaculture	Andalusia
Agrasys	Genetics and biotechnology	Catalonia
Proalt	Diagnosis	Madrid
Absorbol	Ripening control	Madrid
Tach Bioetanol	Biofuels	Madrid
Nutra Omega Biotech	Functional Foods	Galicia
Life Sequencing	Ultrasequencing	Valencia Region
Barnagen	Diagnosis	Catalonia
Anaxomics	Medicinal drug development	Catalonia
Bioglane	Bioactive components	Catalonia
BTI-Teuto	Industrial Biotechnology	Catalonia
D'Enginy biorem	Bioremediation	Catalonia
Endor nanotech	Nanobiotechnology	Catalonia
Laimat	Biomaterials	Andalusia

Geadic Biotec	Cancer diagnosis	Catalonia
Mygen	Diagnosis	Madrid
Abyntek	R&D Antigens and antibodies	Euskadi
Biofinder	Biosensors	Euskadi
Biolan	Biosensors	Euskadi
Idoki	Supercritical fluids technology	Euskadi
Vakunek	Animal Health Care	Euskadi
Bioftalmiks	Ophthalmology	Euskadi
Innoprot	Human Health Care	Euskadi
MDRenal	Human Health Care ( Diagnosis renal diseases)	Euskadi
Bio-aloe.con	Research Plant Extracts	Madrid
Visual Diagnostics	Eye diseases	Madrid
Orphamed	Reprofiling for rare diseases	Castilla-León
Genhelix	Manufacture of biological products	Castilla-León
Oncostem Pharma	Cancer therapy	Castilla-León
Laboratorios Verbia	Bioremediation	Castilla-León
Asteria Biotech	Biofertilizers	Valencia Region
Biopolis Consulting (ES)	Functional nutrition	Valencia Region
Metis Biomaterials	Biomaterials	Valencia Region
Coretherapix	Cell therapy for regeneration of the myocardium	Madrid
Vitrobio	Plant biotechnology	Valencia Region
Infociencia	Biotech clinical research	Catalonia
Bionostra Aplic. Biotec.	Biotechnology	Madrid
AFT	Functional nutrition	Valencia Region
Tech Farmade	Pharmaceutical development	Andalusia
Icon Nanotech	Nanobiotechnology	Andalusia
Biotechnology Consulting	R&D services aquaculture	Andalusia
Vitagenes	Genetic assessment focussing on health care and wellbeing	Andalusia
Seneca Green Catalyst	Enzyme catalysts for biodiesel production	Andalusia
Mycovitro	Biofertilizers	Andalusia
IcINETIC	Bio-information systems	Andalusia
Savia Biotech, SA	Diagnosis for agrifood companies	Andalusia
ADP Biotecnología	Commercial exploitation of biotech patents	Andalusia
Biotech Projects	Biotech enterprise incubator	Catalonia
Bioapter	Biosensors	Madrid
Neuroscience Technologies	Biomedical research in the sphere of neuropathic pain	Catalonia
Omnia Molecular	Development of new methods for discovering antibiotics	Catalonia
Ab BCN (AntiBody BCN)	Reagents for research and diagnosis	Catalonia
Sepmag	Magnetic separation systems for the biotech industry	Catalonia







4. BUSINESS ACTIVITIES UNDERTAKEN

ASEBIO has recorded a total of 79 business alliances, which represents a 52% increase with respect to the poll carried out in 2006. The increase has been more noticeable in the case of alliances between Spanish enterprises, hence leading to a fall in the internationalisation ratio from 43% to 36%. Of these alliances, 22% had at least one partner from a European country, versus the 10% of agreements with US companies (15% in 2006).

Table 4.1 Breakdown of the alliances reported

Companies	Objective
Natraceutical (ES)/ Kraft food (USA)	Developments of ingredients deriving from cocoa
Neocodex (ES)/ Corporación Dermoestética (ES)	Genetic studies on obesity
Advancell (ES)/Fundación la Fe (ES)	Creation of a safety analysis unit for new medicinal drugs
Advancell/Protherics (RU)	Development of the medicinal drug Acadesina
Genetrix(ES)/Advancell (ES)	Joint Venture to create Fenix Biotech
Digna Biotech (ES) / Biotechnol (PT)	Development of the medicinal drug cardiotrofina
Biotoools (ES)/CapitalBlo (CH)	Microarray applications and molecular diagnostic kits
Grífols (ES)/Hospital German Trias/UAB	Gene therapy development in intestinal diseases
Neuropharma/Progenika/Proteomika/NBT/OWL Genomics/Pharmamar/Faes Farma/Rovi	New technologies for preclinical research (Cenit Melius)
Digna Biotech (ES) /AMT (NL)/CIMA (ES)	Development of gene therapy patents
Digna Biotech (ES) / ProPhamaceuticals (USA)	Application of the carbohydrates technology platform in products for Hepatitis C
Seaweed (ES) /CNADC (CH)	Development of biotech applications in agriculture and veterinary fields
Ferrer (ES) / Gendiag (ES)	Joint Venture to create Ferrer Incode
Cellerix (ES)/ Axcan (USA)	Licence of the Cx401 for the treatment of perianal fistulas
Galletas Gullon (ES) and 14 other partners	Study of the incidence of nutrition on chronic diseases (Cenit Higea)
BTI (ES) , Fundación Prodintec (ES), Fundación Inasmet (ES), IBV (ES) and others	Development of biomaterials for implants (Cenit Intelimplant)
Araclon Biotech (ES) /CIBIR (ES)	Development of a predictive kit for Alzheimer's Disease
Entrechem(ES) / Instituto Biomar (ES)	Research in combinatorial chemistry
Entrechem (ES) / Laboratoires Servier (FR)	Research in combinatorial chemistry
Fina Biotech (ES) / Halotech (ES)	Production and world sale of the Halosperm kit
Neuron (ES)/ Histocell (ES)	Joint development of new products
Ingenasa (ES) / Operon (ES)	Research, development and commercialisation of immunochromatography products
Neuropharma(ES) / JSW Research (USA)	Development of transgenic mouse models
Oryzon Genomics(ES)/Genfit (FR)	Markers and therapy for Parkinson's Disease
Oryzon Genomics(ES)/Reig Jofré (ES)	Development of diagnosis and therapy methods (Endomed) for cancer of the endometrium

Companies	Objective
Sistemas Genómicos (ES) / Quirón Hospital Group (ES)	DNA conservation service
Thrombotargets (ES) /Magellan Biosciences Group (USA)	Identification of hits in marine products
Thrombotargets (ES) /Chemotargets (ES)	Identification of hits for cardiovascular diseases
Thrombotargets (ES)/Univ.Sofia (ES)	Global research agreement
Thrombotargets (ES) / Graffinity (D)	Screening collaboration agreement
Thrombotargets (ES) /Instituto Biomar (ES)	Hit identification and optimisation
Genetrix/CCMI/Accenture/Sensia/FUNDAME	Research into new therapeutic targets for the treatment of spinal muscle atrophy GENAME project (Genoma Spain)
Genzyme/ AEAF/Pharmamar/UAB/CNIO/CIBERED	Tools for more effective diagnosing therapies in patients with gene mutations involved in Fanconi's Anaemia FANCOGENE (Genoma Spain)
Sistemas Genómicos/Valentia Biofarma/Instituto Biomar/ IUCT	Therapeutic collisions for myotonic dystrophy: Functional genomics for finding new CTG medicinal drugs (Genoma Spain)
Advancell/Digna Biotech	Nanoencapsulation interferon alfa 5
Digna Biotech/ Laboratorios Ferrer	Licence of the ePCR for diagnosing risk of thrombosis
Biotoools (ES)/Hospital Ramón y Cajal (ES)	Microarray development for controlling lipid metabolism and cell cycle.
Agrasys (ES) / CSIC Sustainable Agriculture Institute (ES)	Development of new varieties of tritordeum and other bioenergy crops
Agrasys (ES) / Agrovegetal (ES)	Development of bioenergy crops
Agrasys (ES) / Saatbau Linz (AU)	Tritordeum development and commercialisation (a new functional cereal with healthy features)
Agrasys (ES) / Limagrain (FR)	Industrial validation of tritordeum (a new functional cereal with healthy features)
Agrasys (ES) / Lantmannen (SE)	Industrial validation of tritordeum (a new functional cereal with healthy features)
Biopolis (ES) / Secugen (ES)	Joint Venture to create Life Sequencing
Biomedal (ES)/Ingeniatrix (ES)/Bionaturis (ES)	Microencapsulation to speed up microbiological trials DIVERTRAP Project
Laimat (ES) / University of Granada (ES)	Biomaterial stability
Laimat (ES) / CSIC Materials Institute(ES)	Joint development of new products
Biobide (ES)/ Laboratorios Dr. Esteve (ES)	Fine tuning of a method using zebra fish for assessing the potential effects of cardiovascular drugs
Palau Pharma, S.A. (ES) / Affectis Pharmaceuticals (D)	Clinical development of cimicoxib as a treatment for depression and schizophrenia
Bionaturis/Neuronbiopharma (ES)	Research of new drugs against neurodegenerative diseases
Bionaturis/COVAP (ES)	Lactomedium Project;
Bionaturis/Advtechind (Hong Kong)	Bioactive molecules
Bionaturis/MBM Sciencebridge (D)	Bioactive molecules
Neuropharma/GAIKER/CCMI/ Biobide	Development of a toxicological assessment model based on in-vivo zebra fish correlation rata versus gene expression profile





Companies	Objective
GAIKER/ IKERLAN/GEMA MEDICAL/ LINEAR CHEMICALS/ECC/Biotools	Development of a Smart-Biocard to detect legionella spp.
Inbiomed/GAIKER/CIEMAT/Cellerix	Genomic and bioproteomic assessment of bio-engineered mouse models for skin pathologies
PROTEOMIKA/ CANVAX/ CIC BIOGUNE/ UNI. VALENCIA/NORAYBIO/GAIKER	Integrated development of a protein chip for colorectal cancer based on markers
GAIKER/ PHARMAKINE	Development of a rapid detection system for angiogene markers, VEGF and endostatine
Gaiker/TEKNIKER/ CSIC International Microelectronics Centre	Biochips for high density and resolution proteomic recognition
GAIKER/IKERLAN/CEIT	Application of a low magnetic field system for detecting Eschericchia coli
Sistemas Genómicos/University of Málaga (UMA) /IAS - CSIC/ INB / University of Córdoba	Genomics applied to olive trees OLIGEN Project (Genoma Spain)
Biopolis (ES) / Tetra Therapeutics (ES)	Biopolis Clinical joint venture
Neocodex (ES)/ F° Alzheimer (ES)	Genomic research for the diagnosis and therapy of neurological diseases
Chimera (Grupo Bionostra - ES) / Mount Sinai School of Medicine	Development of influenza vaccines
Chimera (Grupo Bionostra - ES) / University of Heidelberg	Development of vaccines against cancer of the cervix
Pevesa/Kerry Bioscience (NL), Sheffield Pharma Ingredients (UK)	Culture medium development for diagnosis, Cell Culture fermentation
Pevesa/Natraceutical (ES)	Development of functional ingredients through enzymes
Pevesa/University of Seville	Development of active bio-peptides for muscle cell recovery
Pevesa/Abiasa	Design of probiotic plant ingredients for growth
Pevesa/SuanFarma Inc (USA)	Distribution of Nutraceuticals/Cosmoceuticals products (USA, Canada)
PHARMAKINE/AMAXA (D)	Development of a HTP transfection system of primary cultures
PHARMAKINE/HOSP. LA PRINCESA (ES)	Epithelium-mesenquimal transition (EMT) involvement in the development of peritoneal metastases
A&B Laboratorios de Biotecnología/Guserbiot	Research and development of biological ingredients of microbial origin
EntreChem (ES) / University of Kentucky (USA)	Patent licence to develop new anti-tumour drugs
EntreChem (ES) / Istituto Oncologico della Svizzera Italiana, IOSI, (CH)	Preclinical evaluation of new anti-tumour drugs
Entrechem (ES) / University of Jena (D)	Discovery of new of topoisomerasa inhibitors
Entrechem (ES) / Instituto de Investigaciones Biomédicas (ESP)	Preclinical evaluation of new anti-tumour drugs
IUCT/URQUIMA	Application project of Industrial Biotechnology to Fine Chemistry
IUCT/COGNIS	Co-development of new products
InBio/UPV ( University of the Basque Country)	Development of product and technology for sustained liberation medicinal drugs

5. STRATEGIC PRIORITIES

The items showing the highest increases in their priority rating are those which refer to “Forging alliances with other user companies”, which rises seven places and the “Licence-out technology” which rises four.

**Table 5.1. Analysis of the strategic priorities of Spanish biotech enterprises for 2008, based on a survey of companies associated to ASEBIO. The main variations over the 2007 priorities are highlighted in bold print.**

	Relevance (4= vital for the survival 0= not anticipated)		Change of posición in respect to 2006
Acquire knowledge and/or technology	3,1	▲	+1
Internationalise	3,0	▲	+2
Form alliances with other user companies (pharma, foods)	2,5	▲	+7
Product launches onto the market	2,4	▼	-4
Expand operations to other business areas	2,4	▼	-2
Contract or form alliances with public centres	2,4	▼	-1
Form alliances with other biotech companies	2,0	▲	+1
Enter into clinical/ field trials/ scaling phases	2,0	▼	-3
Licence–out technology	2,0	▲	+4
Recruit foreign experts	1,6	▲	+1
Licence–in technology	1,6	▲	+1
Form a joint venture	1,4	▼	-2
Refocus R&D activities	1,4	▼	-6
Refocus product development	1,0	▼	-8
Externalise production	0,7	=	0
Merge with another company	0,4	▲	+2
Take over a company	0,3	=	0
Reduce operations	0,2	▼	-2




6. INDUSTRIAL PROPERTY AND KNOWLEDGE  
GENERATION


The Madrid Region Circle of Biotechnological Innovation in collaboration with ASEBIO has recorded 144 biotech inventions (applications plus concessions) in 2007, the ownership of which belongs to Spanish companies. These figures represent a 14% increase over 2006.

The ownership of the inventions appearing in this survey belongs to 72 enterprises, versus the 59 recorded in 2006. 65% of these enterprises are located in Catalonia and Madrid.

The Cima Biomedicine Project heads the ranking of most active companies in 2007, ahead of four companies tied for second place: Advancell, Grifols, PharmaMar and Oryzon Genomics.



Graph 6.1. Spanish companies with the highest number of biotech patents (year 2007).





The Madrid Region Circle of Biotechnological Innovation in collaboration with ASEBIO has recorded 144 biotech inventions in 2007

As regards the production of scientific articles for international journals, ASEBIO has identified 60 publications signed by 22 Spanish companies. PharmaMar, Neocodex and BTI stand out as the companies with the largest article production.

Table 6.1. Publications signed by Spanish companies



Empresa	Referencia	Título
Advancell	Rapid Commun Mass Spectrom. 2008;22(2):240-4.	A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations.
Advancell	Toxicol In Vitro. 2007 Oct;21(7):1247-52	Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry.
Advancell	Clin Chim Acta. 2007 Feb;376(1-2):233-6.	Atherogenic and inflammatory profile of human arterial endothelial cells (HUAEC) in response to LDL subfractions
Anaxomics	FEBS Letters, 2008, (in press)	Towards a molecular characterisation of pathological pathways
Biomedal	Nat Methods. 2007 Nov; 4(11):937-42.	In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit
Biomedal	Microb Cell Fact. 2007 Mar 20;6:10.	An improved system for estradiol-dependent regulation of gene expression in yeast.
BTI	Biomaterials 2007;28:4551-4560.	The potential impact of the preparation rich in growth factors (PRGF) in different medical fields
BTI	Trends Pharmacol Sci (In Press).	Delivering growth factors for therapeutics
BTI	J Clin Periodontol (In Press).	5-year clinical experience with BTI dental implants: risk factors for implant failure
BTI	J Periodontology (In Press).	5 year clinical evaluation of short dental implants placed in posterior areas: a retrospective study
CEIFER	Scand J Clin Lab Invest. 2007	Quality specifications for seminal parameters based on clinicians' opinions.
CEIFER	Cell Tissue Bank. 2007;8(4):257-65	Procedure control and acceptance sampling plans for donor sperm banks: a theoretical study.
Cellerix	Int J Colorectal Dis. 2007 Dec;22(12):	An assessment of the incidence of fistula-in-ano in four countries of the European Union.
Era 7	The Journal of Immunology, 2007, 179: 31-35.	Cutting Edge: Natural DNA Repetitive Extragenic Sequences from Gram-Negative Pathogens Strongly Stimulate TLR91
Era 7	Traffic. 2007 Dec 7; : 18088303	Characterization of a Listeria monocytogenes protein interfering with Rab5a.
GAIKER	Biosensors & bioelectronics 2007, 22: 2132-2137	Dna Microdevice For Electrochemical Detection Of Escherichia Coli O157: H7 Molecular Markers





Empresa	Referencia	Título
GAIKER	<i>Molecular cancer therapeutics</i> 2007, 6, (11): 2921-2927	Cannabidiol As A Novel Inhibitor Of Id-1 Gene Expression In Aggressive Breast Cancer Cells
GAIKER	<i>Acta otorrinolaringológica Española</i> 2007, octubre, 1 (1): 1-7	Estudio In Vitro De La Capacidad Protectora E Hidratante De Un Gel Intranasal (In Vitro Study of the Protective and Hydrating Capacity of an Intransal Gel)
InBio	<i>Biopharm Drug Dispos.</i> 2007 Jul;28(5):229-39	In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.
Ingenasa	<i>J Vet Diagn Invest.</i> 2007 Nov;19(6):	Development of a sensitive and specific indirect enzyme-linked immunosorbent assay based on a baculovirus recombinant antigen for detection of specific antibodies against Ehrlichia canis
Laboratorios Leti	<i>Ann Allergy Asthma Immunol.</i> 2007 May;98(5):	Comparison of the allergenicity and Ole e 1 content of 6 varieties of Olea europaea pollen collected during 5 consecutive years.
Laboratorios Leti	<i>Ann Allergy Asthma Immunol.</i> 2007 Apr;98(4):	The use of raw or boiled crustacean extracts for the diagnosis of seafood allergic individuals.
MSD España	<i>FEMS Microbiol Ecol.</i> 2007 Jun;60(3):	High-throughput culturing of fungi from plant litter by a dilution-to-extinction technique.
MSD España	<i>Xenobiotica.</i> 2007 Feb;37(2):	Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach.
Neocodex	<i>Hypertension.</i> 2007 Nov;50(5):	Sex and body mass index specific regulation of blood pressure by CYP19A1 gene variants.
Neocodex	<i>Nat Protoc.</i> 2007;2(7):	Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping.
Neocodex	<i>Pharmacogenomics.</i> 2007 Jul;8(7):	Controlled ovarian hyperstimulation pharmacogenetics: a simplified model to genetically dissect estrogen-related diseases.
Neocodex	<i>BMC Med Genet.</i> 2007 Jan 16	Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels
Neocodex	<i>Hum Reprod.</i> 2007 Feb;22(2):	Molecular analysis of estrogen receptor alpha gene AGATA haplotype and SNP12 in European populations: potential protective effect for cryptorchidism and lack of association with male infertility.
Neuron BPh	<i>Future Virol.</i> 2007 2(3) 239-242	Understanding the relationship between ApoE and HSV-1and its possible significance in Alzheimer's Disease

Empresa	Referencia	Título
Neuron BPh	<i>Aging Cell.</i> 2007 6; 841-842	Apolipoprotein E genotype influences vertical transmission of herpes simplex virus type 1 in a gender specific manner
Neuropharma	<i>J Med Chem.</i> 2007 Nov 29;50(24):	In Vivo Anti-Chagas Vinylthio-, Vinylsulfinyl-, and Vinylsulfonylbenzofuroxan Derivatives.
Neuropharma	<i>Curr Opin Investig Drugs.</i> 2007 Jul;8(7):	Marine-derived drugs in neurology.
Neuropharma	<i>J. Nat. Prod.</i> 2007, 70, 1397–1405	Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure–Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer's Disease.
Neuroscience Technologies	<i>Neurology.</i> 2007; 0: 01.	Neuropathic pain. Redefinition and a grading system for clinical and research purposes
Neuroscience Technologies	<i>Neurological Sciences</i> 2007;28(3):136-41	Questionnaire on neuropathic pain: a European neurologist survey.
Neuroscience Technologies	<i>Journal of Physiology</i> 2007;578:213-232	Velocity recovery cycles of single C fibres innervating rat skin.
OrphaMed	<i>Drug Discovery Today: Therapeutic Strategies, Volume 3, Issue 4, Winter 2006, Pages 445-450</i>	In-Target versus Off-Target allosteric modulators of GPCRs
Palau Pharma	<i>Mol Pharmacol.</i> 2007 Aug;72(2):269-79.	UR-1505, a new salicylate, blocks T cell activation through nuclear factor of activated T cells.
Pharmamar	<i>J Am Chem Soc.</i> 2007 May 2;129(17):	Solid-phase synthesis of oxathiocoraline by a key intermolecular disulfide dimer.
Pharmamar	<i>Bioorg Med Chem.</i> 2007 Aug 1;15(15):	Antiangiogenic versus cytotoxic activity in analogues of aeropylsinin-1.
Pharmamar	<i>J Cell Biochem Año</i> 2007 vol 100(2), pages 339-348	Extreme sensitivity to Yondelis(R) (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Pharmamar	<i>Apoptosis Año</i> 2007 vol 12, pages 395-409	The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway
Pharmamar	<i>Invest New Drugs Año</i> 2007 vol 25(1), pages 9-19	In vitro characterization of the human biotransformation pathways of aplidin, a novel marine anti-cancer drug
Pharmamar	<i>J Proteome Res Año</i> 2007 vol.6 pages1286-1294	Proteomic Analysis of the Resistance to Aplidin in Human Cancer Cells
Pharmamar	<i>Mol Cancer Ther Año</i> 2007 vol.6(4) pages 1310-1316	Levels of p27kip1 determine Aplidin sensitivity



Empresa	Referencia	Título
Pharmamar	<i>lancet oncol Año 2007 vol 8(7) pages 595-602</i>	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Pharmamar	<i>ChemMedChem Año 2007 Descripción vol 2pages 1076-1084</i>	Synthesis and Structure–Activity Relationship of Cytotoxic Marine Cyclodepsipeptide IB-01212 Analogues
Pharmamar	<i>J Org Chem Año 2007 vol 72(10) pages 3790-3799</i>	Double dearomatization of bis(diphenylphosphinamides) through anionic cyclization. A facile route of accessing multifunctional systems with antitumor properties.
Pharmamar	<i>Clin Pharmacol Ther Año 2007 D vol In press pages 1-14</i>	Mechanism-based Pharmacokinetic/ Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia
Pharmamar	<i>Tetrahedron Año 2007 vol 63 pages 2432-2438</i>	Njaoamines A–F, new cytotoxic polycyclic alkaloids from the haplosclerid sponge Reniera sp.
Pharmamar	<i>Leukemia Año 2007 vol 21(12) pages 2399-2405</i>	Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity
Pharmamar	<i>Clin Pharmacokinet Año 2007 vol 46(10) pages 867-884</i>	Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis®) in Cancer Patients
Pharmamar	<i>J Pharmacol Exp Ther Año 2007 vol In press pages 1-29</i>	Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/JNK activation in human melanoma cells
Sensia	<i>Anal Bioanal Chem. 2007 May;388(1):</i>	Part per trillion determination of atrazine in natural water samples by a surface plasmon resonance immunosensor
Sensia	<i>Anal Bioanal Chem. 2007 Feb;387(4)</i>	Multi-analyte SPR immunoassays for environmental biosensing of pesticides.
Sensia	<i>Biosens Bioelectron. 2007 Feb 15;22(7):</i>	Optical immunosensor for fast and sensitive detection of DDT and related compounds in river water samples.
Sistemas Genómicos	<i>ASEBIR. 2007;12:36-42.</i>	Gestión de calidad en los laboratorios de DGP.(Quality management in DGP laboratories)
Sistemas Genómicos	<i>UNE. 2007;220: 22-26.</i>	La calidad en genética. (Quality in genetics)
Vircell	<i>Clin Vaccine Immunol. 2007 Feb;14(2):</i>	Vircell assays for detection of antibodies against Legionella pneumophila.

7. RED BIOTECHNOLOGY

According to a survey conducted by ASEBIO among its member companies, during 2007, 28 companies undertook a total of 122 projects concerning medicinal drugs and diagnostic systems for human use and 12 products for animal health care.

Oncology, infectious diseases, inflammation, cardiovascular disorders and neurological diseases are the areas that account for the largest number of innovations in therapies and diagnosis.

Among the 19 companies that are developing drugs, the most outstanding is Pharmamar, which in 2007 marketed the first innovative anti-cancer drug developed in Spain, Yondelis. There are other products in the advanced clinical phase (phase III), including the Cellerix cell therapy for treatment of complex fistulas and Palau Pharma’s coronary Stent in the cardiovascular field. Other Spanish biotech companies, such as Neuropharma, Advancell, Digna Biotech, Archivel, Thrombotargets or Fina biotech, have more recently entered into clinical phases.

Furthermore, the ASEBIO survey reports 29 new disease diagnosis and prognosis systems, some are which are soon to come out onto the market. Likewise, in the medical supplies field, the PRGF regeneration technology developed by BTI, a company from the Basque province of Álava, also stands out.

As far as animal health care is concerned, there were a total of 12 new products reported in 2007, most of which are indicated for Infectious Diseases.

8. GREEN BIOTECHNOLOGY

Some of the most outstanding areas in the Agriculture and forestry field are products developed for biological control and biofertilization, where enterprises have been created that are specifically devoted to this area.

As far as transgenic products are concerned, Spain saw a spectacular increase (40%) in the acreage devoted to maize protected against borer beetle infestation, thus becoming EU leader in this crop cultivation.



Pétalo de rosa

The impact of biotechnology and food not only represents improvements in the nutritional properties of certain products and the development of new foodstuffs, but also food control, with ever more sophisticated methodologies and techniques aimed at assuring its quality, safety and traceability from the production process through to the end consumer.



As a result of this technological and industrial revolution, the Spanish have stopped perceiving food safety as one of the main problems affecting them. Issues referring to foodstuffs stopped appearing on the list of the 30 most important problems concerning the public in January 2005. (Source: Opinion polls periodically taken by the Spanish Sociological Research Centre, CIS)

9. WHITE BIOTECHNOLOGY

Within the area of biotech applications for energy production, the creation of new companies aimed at obtaining biofuels from commodities is worthy of mention. Spain is currently an outright leader in the biofuels manufacturing industry, which should act as a driver for biotech research in this area.

Companies devoted to bioremediation and biodecontamination have developed new products in 2007 to be applied to these two spheres.





10. THE FINANCIAL ENVIRONMENT

The majority of seed capital investments are concentrated in companies that are less than 5 years old; nevertheless, the most outstanding financial transactions in more veteran companies are equity loans not exceeding €1 million.

In 2007, for the first time ever, an investment in a Spanish company was placed among the most important operations of the year in Europe.

As far as the Stock Market (the Alternative Securities Market) is concerned, there is a desire among many of the Spanish biotech companies to go public.



State-wide public entities were the leading bodies in awarding equity loans. Some public/private funds also played an outstanding role.

In 2007, for the first time ever, an investment in a Spanish company was placed among the most important operations of the year in Europe

**Table 10.1. Main financial operations in the Spanish biotechnology sector in 2007.** *Source: Drawn up by ASEBIO based on information provided by its members, data published in the press and the Spanish Risk Capital Association, ASCRI.*

Company	Investor	Item Heading	investment (million)
Exxentia	Puleva Biotech	Takeover (100%)	37.50
Cellerix	LSP, Ventech, YSIOS, Roche and Novartis Venture Funds and Genera, Biopartners (Grupo A&G)	Capital enlargement	27.20
Zeltia	Santander Investment	Capital enlargement	15.00
Advancell	Ceosa, Talde, A.Vila Casas, Unisco, BCN Empren and others	Capital enlargement	7.50
Puleva Biotech	Pescaderías Coruñesas	Holding (5%)	7.20
Bionostra	Several	Capital enlargement	7.00
UniBifocus	Caixanova	Holding in the fund	6.00
KingFood (Australia)	Natraceutical	Takeover (100%)	5.40
Orphamed	Suan Biotech, Clave Mayor, SODICAL	Seed capital	4.00
Vivotecnia	Ronda Vida, INICAP I	Capital enlargement	3.50
Digna Biotech	Clave Mayor	Capital enlargement	3.00
Savia Biotech	Cajamar	Seed capital	2.60
Biopolis	CLAS/Talde/CSIC	Capital enlargement	2.50
Advancell	CDTI	Loan	2.40
Thrombotargets	Biotech Angels	Capital enlargement	2.00
Thrombotargets	Biolead Capital	Capital enlargement	2.00
UniBiofocus	Xesgalicia	Holding in the fund	2.00
Viscofiber (Canada)	Natraceutical	Takeover (100%)	2.00

Company	Investor	Item Heading	investment (million)
Noray BG	Orza	Capital enlargement (33%)	1.80
Biotoools	CDTI	Loan	1.16
Biotoools	Inibsa	Capital enlargement	1.08
Suan Biotech	Capital Riesgo Madrid	Holding in the fund	1.00
Archivel	ENISA	Equity loan	0.85
Genmedica	Uninvest-Unirisco	Capital enlargement	0.80
Genmedica Therapeutics	BCN Ventures	Capital enlargement	0.80
Idifarma	Clave Mayor	Expansión	0.80
Thrombotargets Europe	ENISA	Capital enlargement	0.60
Ojer Pharma	Clave Mayor	Seed capital	0.50
Savia Biotech	Iniciativas Económicas de Almería	Seed capital	0.50
Ojer Farma	SODENA	Seed capital (26%)	0.47
Algenex	Uninvest-Unirisco	Seed capital	0.45
3P Biopharmaceuticals	Sodena	Seed capital	0.42
TCD Pharma	ENISA	Seed capital	0.35
Neuroscience Technologies	CDTI	NEOTEC	0.32
Era Biotech	BCN Ventures	Capital enlargement	0.30
Lactest	ENISA	Seed capital	0.30
Sensia SL	MCC Componentes and MMC Inversiones	Partial takeover (20%)	0.30
Bionaturis	CDTI	NEOTEC	0.28
Bionaturis	ENISA	Equity loan	0.25
One Way Liver Genomics	ENISA	Capital enlargement	0.25
Owl Genomics	Seed Capital de Bizkaia	Seed capital	0.25
Biomaslinic	Uninvest-Unirisco	Seed capital	0.23
Inmunostep	Uninvest-Unirisco	Capital enlargement	0.23
Vacunek	Seed Capital de Bizkaia	Seed capital	0.21
Bionaturis	Univen Capital	Capital enlargement	0.20
Vita Aidelos	Caixa Capital Risc	Seed capital	0.18
Fenix Biotech	Genetrix, Advancell	Seed capital	0.15
Neuroscience Technologies	Private partners	Capital enlargement	0.14
Genetadi	Seed Capital de Bizkaia	Capital enlargement	0.10
Histocell	Seed Capital de Bizkaia	Capital enlargement	0.10
Laboratorio Análítico Bioclínico	Iniciativas Económicas de Almería	Seed capital	0.099165
Cenbimo	Xesgalicia	Capital enlargement	0.085
Inbionova Biotech	Murcia Emprende	Start-up	0.07



Company	Investor	Item Heading	investment (million)
Laimat	Invercaria (Programa Campus)	Seed capital	0.067
Rara Avis Biotec	CDTI	NEOTEC	n.a/0.26
Carbongén	ENISA/Talde	Start-up	0.3/n.a
Infinitec Activos	BCN Ventures	Capital enlargement	0.05
3P Biopharmaceuticals SL	Suan Farma, Idifarma and Dro Biosystems	Seed capital	Not Available
3P Biopharmaceuticals SL	Activos y gestión accionarial, Corpcan, Caja Rural de Navarra, Real de Vellon, Infu Capital , Cinamar , Masaveu de I+D and Grupo Paramus.	Seed capital	Not Available
Ab Bcn	CDTI	NEOTEC	Not Available
Agrasys	CDTI	NEOTEC	Not Available
Alternative Gene Expression	CDTI	NEOTEC	Not Available
Bioapter	Möbius	Seed capital	Not Available
Biofinder	CDTI	Seed capital	Not Available
Bioiliberis	CDTI	NEOTEC	Not Available
Biotoools	Inibsa	Share repurchase	Not Available
Calantia Biotech	CDTI	NEOTEC	Not Available
Clavesuan	Suan Biotech	Seed capital	Not Available
Era7	Socios fundadores	Capital enlargement	Not Available
Halotech	Suan Biotech	Seed capital	Not Available
Histocell	Noray BG	Takeover (80%)	Not Available
Iberchem	Capital Alianza	MBO	Not Available
Idoki Scf Technologies	CDTII/Seed Capital de Bizkaia	Seed capital	Not Available
Ingenasa	Operon	Partial takeover (10%)	Not Available
Lorgen	Lider XXV	Partial takeover (70%)	Not Available
Microbial	CDTI	NEOTEC	Not Available
Neuroscience Technologies	CIDEM	Loan	Not Available
Omnia Molecular	CDTI	NEOTEC	Not Available
Orphamed	ADE Capital Sodical	Seed capital	Not Available
Pevesa	Suan Biotech	Seed capital	Not Available
Pharmakine	Volumen Comunicación	Capital enlargement	Not Available
Progenika	Orza	Takeover (10%)	Not Available
Sistemas Genómicos	Eresa, Inmotec	Share change (12%)	Not Available
TCD Pharma	Najeti Capital	Seed capital	Not Available

11. THE SOCIAL ENVIRONMENT (CITIZENS' CONSENSUS DEBATE ON ADVANCED THERAPIES)

ASEBIO organised a debate for citizen consensus to explore the uncertainties that advanced therapies arouse in Spanish society, by fine-tuning a methodology for the public to participate.

Box 11.1 shows the main conclusions reached by the Citizens' Panel:

- The Panel demanded more information and dissemination regarding the potential benefits, scope and advantages offered by advanced therapies.
- The Citizens' Panel expressed its reservations about a scenario in which advanced therapies became an exclusive service which could only be enjoyed by a wealthy minority in technologically advanced societies. In view of this threat, they advocate for equality between regions and social classes.
- It concluded that the current situation of scientific advancement should be considered inchoate and they agreed that the majority of its contributions are yet to come.
- It demanded greater public and private sector collaboration and funding of this research, for both highly prevalent and also rare diseases.
- It underlined the need for wider awareness and a deeper ethical debate as regards the use of viable embryos and the use of cells from unviable embryos.
- It demanded respect for human dignity and the principle of precaution as the main values underpinning research.





Who is Who?







Who is Who?

## Business Members



### 3P Biopharmaceuticals

**Sector:** Health and Wellness

**Mission:** Development of production systems and production of active therapeutic principles for studies pre clinical, clinical phases I, II and III, and in some commercial case. Processes using yeasts, bacterial fermentation and cells of mammals. Processes under GMP conditions. Processes of cellular therapy and cellular culture.

**Products:** Development of expression systems and production of proteins. Proteins, Interleukinas, monoclonal antibodies, vaccines and adyuvantes. Other therapeutic substances of peptidic nature. Development of production systems and elaboration units of cellular therapy. Development services and cultivation of cells. Elaboration DMF (Drug Master File). Service of Regulatory.

**Interest areas for futures colaborations/alliances:** Projects to industrialize products and services in cellular therapy or cellular culture. Biosimilars development. Collaboration with companies non EU in adaptation to the European market and regulatory. Integral service of development, production, dose systems, and clinical until arriving to the registration like medication, well for the own capacities or with the associate companies.

**Contact**

Polígono Mocholí, Plaza CEÍN nº 5  
Noain  
31110 Navarra

Tel.: + 34 948 346 480  
<http://www.3pbio.com>

**Dámaso Molero**  
General Manager  
[dmolero@3pbio.com](mailto:dmolero@3pbio.com)



### A&B Laboratorios en Biotecnología, S.A

**Sector:** Chemical-Biological

**Mission:** Development of bioproducts for biodetergents and bioremediation products.

**Products:** Research, manufacturing and marketing of industrial chemical and biological products.

**Interest areas for futures colaborations/alliances:** Selection of natural micro-organisms. Enzyme production. Industrial fermentation. Ecodesign.

**Contact**

Paduleta, esquina Jundiz  
Vitoria  
01015 Alava

Tel.: + 34 945 291 616  
Fax: + 34 945 292 939  
<http://www.ab-laboratorios.com>

**Jon Kepa Izaguirre**  
General Manager  
[kepa@ab-laboratorios.com](mailto:kepa@ab-laboratorios.com)



### Adecco Medical & Science

**Sector:** Human Resources Scientific Area

**Mission:** Provide HR services for the medical, science, pharmaceutical and biotechnology industries such as search and selection services of specialized profiles, specialized training and HR consulting with a proven know-how within each area.

**Products:** Search and selection services for medical & science profiles focused in research, sales and marketing activities within the pharmaceutical & biotechnology sectors. Technical training consulting for the pharmaceutical and science areas. Occupational health & safety consulting.

**Interest areas for futures colaborations/alliances:** Participation in working groups, publications and workshops. Provide business solutions to different needs in the HR area.

**Contact**

C/ Goya, 29  
Madrid  
28001 Madrid

Tel.: + 34 932 722 870  
Fax: + 34 932 722 878  
<http://www.adecco.com>


**Oscar Porcel**  
National Science Manager  
[Oscar.porcel@adecco.com](mailto:Oscar.porcel@adecco.com)



Business Members

asebio

### Advancell in Vitro Cell Technologies, S.L.



**Sector:** Human Health Care / Therapeutic

**Mission:** To contribute to obtaining new medicines through new technologies acquired in Spanish universities and / or developed by Advancell:

- ❖ Developing and marketing in vitro cell models in service or product form (kits).
- ❖ Developing Advancell technologies and products until the clinical concept trial stage.

**Products:** **CacoReady:** a tool designed to optimise pre-clinical screening regarding the viability of orally administering compounds of a different nature. **HUVECs:** Umbilical vein endothelial cells. **HUAECs:** Umbilical artery endothelial cells: Adipocytes / Microsomes. **KITS (under development):** Adipocell / MicrosomeCell

**Services:** Screening. Customised research: ADME, cancer, inflammation, biocompatibility, cosmetics and skin biology. Pharmaceutical developments: ADV-P1 (chronic lymphocytic leukaemia B cells). ADV-P2 (diabetes). ADV-P3 (psoriasis). ADV-P4 ( haemodynamics). ADV-P5 ( solid tumour progression).

**Interest areas for futures colaborations/alliances:** Technologies or products in early phases, complementary or with strategic value for ADVANCELL: **Cancer - Cosmetics - Others.**

**Contact**

Parc Científic de Barcelona  
Baldri Reixac, 10-12  
Barcelona  
08028 Barcelona

Tel.: + 34 934 034 545  
Fax: + 34 934 034 544  
<http://www.advancell.net>

**Luis Ruiz Ávila**  
General Manager  
[advancell@advancell.net](mailto:advancell@advancell.net)

### Agrasys, S.L.



**Sector:** Agricultural Biotechnology

**Mission:** AGRASYS is a R&D-based company which uses advanced plant breeding technologies to produce novel crop varieties with added value. These new varieties are targeted at specific market opportunities, identified by the company or its business partners. Current projects and products of the company are directed at the market sectors of functional foods and biofuel crops.

**Products:** The first product being brought to market is a novel cereal type which offers health benefits and can be used in the production of a range of cereal-based foods. The same techniques are used in the development of improved food crop varieties for bioethanol. The company has experience of consultancy in the Agbiotech area.

**Interest areas for futures colaborations/alliances:** Agrasys works with companies and public research centers, as the technology provider, contractor of research services or partner in product development and marketing. Examples of collaborations; breeding of new crop germplasm as raw material for food or industrial uses, co-development of new food applications based on varieties with functional components, genetic engineering of industrial crops.

**Contact**

Parc Científic de Barcelona  
Baldri i Reixac 10-12,  
Barcelona  
08028 Barcelona

Tel.: + 34 934 020 278  
Fax: + 34 934 020 278  
[www.agrasys.es](http://www.agrasys.es)

**Pilar Barceló Ensesa**  
Administrator  
[pilarbarcelo@agrasys.es](mailto:pilarbarcelo@agrasys.es)





## Who is Who?



## Alexion Pharma Spain SL

**Sector:** Pharmaceutical

**Mission:** Pharmaceutical product development and commercialization.

**Products:** Humanized monoclonal antibody for the treatment of the Paroxistic Nocturnal Hemoglobinuria

**Interest areas for futures colaborations/alliances:** Biotechnology applied to general medicine. Innovative drugs. Orfan drugs commercialization in rare diseases.

**Contact**

World Trade Center Moll de Barcelona, s/n  
Edificio Sur, 2ª planta.  
Barcelona  
08039 Barcelona

Tel.: + 34 933 443 260  
Fax: + 34 933 443 299

**Jordi Casals Ferragut**  
Director General  
casalsj@alxn.com



## Alma Consulting Group España

**Sector:** Operational Consulting

**Mission:** Our mission is to identify and obtain financing and savings for our customers. We contribute to our client's competitiveness through measurable actions. Professionals of ALMA Consulting Group work day by day to boost your growth through Innovation, providing the resources you need to finance your Research and Development potential, with a constant commitment for optimisation and security.

**Products:** **Areas of expertise:** Financing of Innovation. Property Tax. Non-strategic purchasing: energy, telecoms, office cleaning, temporary manpower.

**Interest areas for futures colaborations/alliances:** We create a long-term partnership with our customers in order to provide an outstanding support to improve their results.

**Contact**

María de Molina 1, 1º D  
Madrid  
28006 Madrid

Tel.: + 34 915 750 301  
Fax: + 34 914 355 386  
<http://www.almacg.com>

**Marta Orueta**  
Marketing and Communication  
Responsible  
morueta@almacg.com  
**Juan Antonio Costa**  
Sales and Marketing Manager  
jacosta@almacg.com



## Amgen, S.A

**Sector:** Biotechnology, Medicines for human use

**Mission:** To be the best company in human therapies, using science and patient service innovation.


**Products:** Treatments for the complementary care cancer and anaemia, rheumatoid arthritis and other autoimmune diseases. Amgen carries out active research programmes in nephrology, haematology, oncology, inflammations, metabolic, and bone disorders and neuroscience.

**Contact**

World Trade Center Barcelona.  
Muelle Barcelona Edificio Sur, 8ª planta  
Barcelona  
08039 Barcelona

tel.: + 34 936 001 900  
fax: + 34 933 019 009  
<http://www.amgen.es>

**Juan Carlos Esteban**  
Corporate Communication  
jesteban@amgen.com



Business Members

asebio

## Araclon Biotech, S.L.

**Sector:** Biotechnology - Human healthcare.

**Mission:** Research and development of neurodegenerative diseases therapies and diagnostics methods.

**Products:**

**Under development:**

- Alzheimer disease blood diagnostic tests.
- Alzheimer disease therapy.

**Contact**

Paseo de la Independencia, 30, 2ªA  
Zaragoza  
50004 Zaragoza

Tel.: +34 976 796 562  
Fax: +34 976 217 805

**Guillermo de Vilchez Lafuente**  
Managing Director  
gdevilchez@araclon.com



## Archivel Farma, S.L.

**Sector:** Pharma

**Mision:** Clinical development of vaccines.

**Products:** Therapeutic vaccine against Latent Tuberculosis Infection.

**Interest areas for futures colaborations/alliances:** Research and Development on new biological drugs.

**Contact**

C/ Fogars de Tordera, 61  
Badalona  
08917 Barcelona

Tel.: + 34 934 972 456  
Fax: + 34 934 972 457  
<http://www.archivelfarma.com>

**Jaume Amat**  
General Director  
archivel@archivelfarma.com



## Artbiochem, S.L.

**Sector:** Biotechnology

**Mision:** Investigation and development of new enzymes and biomolecules. Development of new test for determination and quantification of metabolites using artichoke peroxidase.

**Products:**

- ❖ Peroxidase, Protease, High DP Inulin, Polyphenol Extract from Artichoke.
- ❖ R+D Services from extraction and purification of enzymes and others biomolecules.

**Interest areas for futures colaborations/alliances:**

- ❖ Development of new applications from high Dp inulin in biomedical sector.
- ❖ Development of tests for clinical diagnostics with companies of this sector for the detection of different diseases.
- ❖ Associates' search for the distribution of our products.
- ❖ Bioremediation.
- ❖ Microbiology y Fermentation.

**Contact**

Polígono Industrial La Capellanía  
Vial 1, Parcela 41, Aptdo 3  
Archena  
30600 Murcia

Tel.: 968 688 217  
Fax: 968 688 217  
[www.artbiochem.com](http://www.artbiochem.com)

**Jose Luis Vidal**  
Financial Manager  
jvidal@artbiochem.com  
**Francisco Palazón**  
Commercial Manager  
fpalazon@artbiochem.com





## Who is Who?



## Asac Pharma, S.A

**Sector:** Human Health Care

**Mision:** Research into drugs based on the active principles of medicinal plants, including those from traditional cultures and uses.

**Products:** A wide range of products comprising the following lines: Cosmetics. Dietetics. Phytobioextracts. Pharmaceutical specialties. Raw materials.

**Services:** Manufacturing of Pharmaceutical Specialties.

**Contact**

Sagitario 14  
Alicante  
Alicante

Tel.: + 34 965 280 312  
Fax: + 34 965 117 306  
<http://www.asac.net>

**Angel Sánchez-Covisa Villa**  
Chairman  
[scovisa@asac.net](mailto:scovisa@asac.net)



## Asteria Biotech, S.L.

**Sector:** Sector: Human health, health animal, agrifoodstuffs

**Mission:** Biological potenciador for the growth and vegetal development, to biological agriculture and integral, obtained from extracts of marine microalgae and microalgae green-blue.

**Products:** Nutritional supplements for human consumption. Additives for animal foods. Biofertilizers for agriculture.

**Contact**

Avda. Cortes Valencianas 48 4ª  
Valencia  
46015 Valencia

Tel.: + 34 902 110 190  
Fax: + 34 902 110 191  
[www.asteriabiotech.es](http://www.asteriabiotech.es)

**Alberto Perez Pardo**  
Unique Administrator  
[info@asteria.es](mailto:info@asteria.es)



## Bayer Bioscience N.V.

**Sector:** Agriculture, Environment-Biotechnology

**Mission:** Bayer Bioscience N.V. is one of the main biotech innovation centres of Bayer CropScience AG, a subgroup of Bayer AG. The objective of the excellence centre is to integrate plant biotech research with the business demands of BayerBioscience to optimise innovating processes in a responsible and sustainable way. Drawing up crop management solutions (pest and weed control), researchers use genetic engineering to discover new features.

**Products:** Patents, *know-how*. Crops of high agronomic interest, with new features applied to modern crossing techniques.

**Interest areas for futures colaborations/alliances:** Agriculture, Environment-Biotechnology.

**Contact**

Technologiepark 38  
Gent  
B-9052 Gent-Belgium

Tel.: +32 92 430 468  
Fax: +32 25 356 331  
[www.bayercropscience.com](http://www.bayercropscience.com)

**Stefania Meloni**  
Registration Manager Spain and UK-  
Regulatory Affairs  
[Stefania.meloni@bayercropscience.com](mailto:Stefania.meloni@bayercropscience.com)



Business Members

asebio

## Bioalma



**Sector:** Bioinformatics

**Mission:** Bioalmas objective is the development of information systems that help the researcher in biomedicine to manage and analyze the information in the literature, to research more efficiently and to reduce the development time of new products.

**Services:** Novoseek is a biological knowledge system that manages information extracted directly from the scientific literature using the most advanced text mining techniques. It provides powerful search and visualization capabilities to navigate the knowledge network and contains functionality to easily identify relevant information.

**Interest areas for futures colaborations/alliances:** Bioalma is interested in the application of information technology techniques on other biomedical bibliographic sources different from the scientific literature and the collaboration with biotech companies for the development of product that use information extraction for target discovery and validation and functional analysis of groups of genes or proteins.

**Contact**

Ronda de Poniente, 4 Bajo C-D  
Tres Cantos  
28760 Madrid

Tel.: + 34 911 417 150  
Fax: + 34 911 417 151  
<http://www.bioalma.com>

**Luis Cornide**  
CEO  
[lcornide@bioalma.com](mailto:lcornide@bioalma.com)

## Bioaurum Solutions, S.L.



**Sector:** Technology Transfer and Innovation Management in Life Sciences

**Mission:** Technology Transfer and Innovation Management in Life Sciences. Spreading biotechnology uses in traditional sectors and in rural areas.

**Services:** Strategic Consulting in Life Science Sector. Designing public policies in Biotechnology sector. Managing Private-Public consortium.

**Contact**

Plaza de las Salesas 7, 2º Izq  
Madrid  
28004 Madrid

Tel.: +34 913 197 603  
Fax: +34 913 197 563  
<http://www.bio-aurum.com>

**Fidel Rodríguez Batalla**  
Director  
[solutions@bio-aurum.com](mailto:solutions@bio-aurum.com)





## Who is Who?



Business Members

asebio



## Biobide

**Sector:** High Throughput Screening (HTS)

**Mission:** Biobide is a newly founded biotech company for the testing or automatic screening of new potential drugs using the zebra fish as the model animal. Biobide is structured on a technological platform that integrates zebra fish disease models, robotics, optical analysis and bio-IT tools, producing highly informative, low-cost results that give rise to a competitive advantage for companies involved in pharmaceutical product development.

**Products:** Development of animal models of human diseases. Target identification and validation. In vivo screening (High Throughput molecule screening). General, specific and genetic toxicity studies. Teratogenesis studies. ADME studies.

**Services:** **Functional genomics services:** Action mechanism studies. Protein function studies. Biological route dissection.

**Interest areas for futures collaborations/alliances:** The collaboration agreements subscribed by the company include both public and private research centres and companies. Company policy consists of setting up agreements with agents who not only possess quality research capacity but also undertake applied research projects that are complementary to our company's own activities, thus maximising the investment on all fronts.

**Contact**

Paseo Mikeletegi, 56  
Donostia-San Sebastián  
20009 Guipúzcoa

Tel.: + 34 943 309 360  
Fax: + 34 943 309 370  
<http://www.biobide.es>

**Idoia Ruiz de Azua**  
General Manager  
[ruizdeazua@biobide.es](mailto:ruizdeazua@biobide.es)



## Bio-Ges Starters

**Sector:** Biotechnology

**Products:** Starters for the agricultural and food industry.

**Contact**

Pº Condesa de Sagasta, 10  
León  
24001 León

Tel.: + 34 987 876 135  
Fax: + 34 987 225 638

**Agustín Florez Moran**  
Managing Director  
[marian@serfisa.es](mailto:marian@serfisa.es)



## Biokit, S.A.

**Sector:** Health Care

**Mission:** Research, production and distribution of clinical diagnostic reagents (IVD).

**Products:** Over 120 diagnostic products for the field of infectious diseases and plasmatic proteins.

❖ **Reagents:** 5 differentiated products depending on the different technologies used: Manual tests. Immunoturbimetric tests. Immunochromatographic tests. Immunoenzyme assay. Chemoluminescence

❖ **Raw materials:** High quality antigens for hepatitis B, rubella, toxoplasma, Lyme disease, syphilis, VHS1 and streptolysin-O, together with antibodies for hepatitis B, streptolysin-O, rotavirus, PCR and ferritin.

**Contact**

Can Malé, Lliçà d'Amunt  
Barcelona  
08186 Barcelona

Tel.: + 34 938 609 000  
Fax: + 34 938 609 029  
<http://www.biokit.com>

**Joan Guixer**  
Quality Assurance Manager  
[jguixer@biokit.com](mailto:jguixer@biokit.com)

## BioMarin Europe Ltd. Sucursal en España

BiOMARIN

**Sector:** BioPharmaceutical

**Mission:** BioMarin seeks to develop product candidates that: Address currently unmet medical needs. Suggest a clear-cut development profile. Provide an opportunity to be first-to-market.

**Products:** Aldurazyme. Naglazyme. Kuvan.

**Interest areas for futures collaborations/alliances:** Metabolic Diseases. Enzyme Replacement Therapies.

**Contact**

Puertas Verdes, 49 - Ciudadcampo  
San Sebastián de los Reyes  
28707 Madrid

Tel.: + 34 800 808 508  
Fax: + 34 800 808 708

**Felis Iglesias**  
Country Manager Iberia  
[figlesias@bmrn.com](mailto:figlesias@bmrn.com)

## Biomedal, S.L.



**Sector:** Biotechnology

**Mission:** To develop new, innovating technologies for the progress of post-genomic research and the efficient industrial production of new biomolecules that are useful for society.

**Products:** Genetic engineering tools for cloning, expression and purification of recombinant proteins and their related products.

**Services:** The design of specialised strains, production of recombinant proteins, sequencing, DNA synthesis, DNA analysis, consultancy and technology transfer.

**Interest areas for futures collaborations/alliances:** Expression and purification of recombinant proteins, protein analysis, molecular diagnostics, proteomics, etc.

**Contact**

Avda. Américo Vespucio, 5-4.  
Planta 1, módulo 12  
41092 Sevilla

Tel.: + 34 954 081 276  
Fax: + 34 954 081 279  
<http://www.biomedal.com>

**Ángel Cebolla Ramírez**  
General Manager  
[acebolla@biomedal.com](mailto:acebolla@biomedal.com)

## Bionostra Group



**Sector:** Sector: Foodstuffs/ Animal Healthcare Diagnostics/ Diagnostics/ Production

**Mission:** Group of biotech businesses created in the year 2000 and constituted by the businesses Bionostra, Bioalma and Microbionta.

**Products:** **Bionostra:** R&D of vaccines of new generation and biotech services in the area animal health, human health and agrofood. **Bioalma:** bioinformatics solutions. **Microbionta:** research of the therapeutic antibodies for the human health.

**Services:** Detection and quantification of GMOs in foods. Identification and authentication of species. Genotyping. Marker selection.

**Contact**

Ronda Poniente 4, 2º C y D  
Tres Cantos  
28760 Madrid

Tel.: + 34 918 060 068  
Fax: + 34 918 060 349  
<http://www.bionostra.com>

**Ana Carmen Martin**  
Biotechnology Applications Manager  
[anac@bionostra.com](mailto:anac@bionostra.com)



## Who is Who?



## Bioorganic Research and Services S.L. (Bionaturis)

**Sector:** BIONATURIS offers products as well as research-technological services to all user sectors of Red, Green and White Biotechnology. These include pharmaceutical, food-agriculture, cosmetic, natural medicine, or nutraceutical, among others.

**Mission:** Using knowledge to help society.

**Products:** BNT PRODUCTS. wide range of added value products to its customers. Extracts, fractions, libraries, quality chemicals, recombinant proteins at industrial scale; set a broad catalogue where enterprises and research centers can meet their needs.

**Services:** BNT PLATFORMS: BIONATURIS offers enterprises and research centers the most up-to-date technologies within our range of activity. **SIDENA HTD (High Throughput Dereplication):** Protein Interaction Analysis (Bioacore); low-cost recombinant protein manufacturing at industrial scale.

**Interest areas for futures colaborations/alliances:** Bionaturis' R&D+i area is looking for partner interested in: creating international network, co-development of research projects, technology transfer agreements, licensing-in, licensing-out. Bionaturis has established external R&D relationships with other partners in the industry and academic institutions into the following areas: Red Biotechnology (human health); pre-clinical investigations; pre-clinical studies; nanomedicine; drug delivery. Looking for out-license agreements and manufacture contract with biopharmaceutical companies.

### Contact

C/ Doctor Duarte de Acosta nº 5.  
Polígono Industrial Las Salinas.  
El Puerto de Santa María  
11500 Cádiz

Tel.: + 34 956 547 346  
Fax: + 34 956 547 346  
<http://www.bionaturis.com>

**Victor Infante**  
R&D Director  
[victor.infante@bionaturis.com](mailto:victor.infante@bionaturis.com)



## Biopolis, S.L.

**Sector:** Industrial Biotechnology

**Mission:** Research projects and microbial biotech development.

**Products:** The design, selection, characterisation and production by fermentation of bacteria, yeasts and filamentous fungi and cellular metabolites obtained from these (proteins, enzymes, nucleic acids, polysaccharides). Fine tuning of its industrial applications in the agrifoodstuff and pharmaceutical fields.

### Contact

Polígono la Coma s/n  
Paterna  
46980 Valencia

Tel.: + 34 963 160 299  
Fax: + 34 963 160 367  
<http://www.biopolis.es>

**Marta Tortajada**  
Head of the Molecular Biology Laboratory  
[Marta.tortajada@biopolis.es](mailto:Marta.tortajada@biopolis.es)



Business Members

asebio

## Bioreply, S.L.

**Sector:** Human Health Care, Animal Health Care, Agriculture and Food

**Mission:** The use of ultra-weak photon emissions of biological systems as an analytical tool. The building of bio-sensors and chemical sensors.

**Products:** ELISAs for plague pesticides; Tiabendazol, Imazalil and chlorpyrifos. Molecular probe for mercury detection.

**Services:** Measurement of photon emissions: Toxicity assays. Detection of heavy metals: mercury.

**Interest areas for futures colaborations/alliances:**

Nanotechnology

### Contact

Asensi, 24, 4ª Planta  
Castellón  
12002 Castellón

Tel.: + 34 696 919 787  
Fax: +34 964 202 365  
<http://www.bioreply.com>

**Javier Ramírez**  
Legally Appointed Representative  
[jramirez@bioreply.com](mailto:jramirez@bioreply.com)



## Biot

**Sector:** Power. Agroambiental. Nourishing

**Mission:** BIOT is a Biotech Enterprise group focus on innovation and R&D in Microbiology. Goals are achieved from the interaction between different BIOT Companies and Research Groups from Universities, Research Institutes and other Companies as well. BIOT develops reliable solutions, products and methodologies based on microorganisms in the areas of agro-food, environmental and bioenergy production.

### Products:

❖ **Selected strains of high biotechnological interest for different industrial sectors:**

Probiotics, Biofuel, producers: methane, ethanol and biodiesel, Bioplastic producers, Soil and water decontamination.

❖ **Enzymes and biomolecules from microorganisms of high industrial interest:**

Genetic constructions for improving microbiological processes.

**Services:** Selection, isolation, quantification and identification of microorganisms using biochemistry and genetics techniques. Genetic Engineering Service of microorganisms. Analysis of microbial communities in terrestrial and aquatic ecosystems. Design and conservation of microbiological resources and culture collections of biotechnological interest. Consulting and advice in the field of Microbiology. Innovation, R&D Project Performing and Management.

**Interest areas for futures colaborations/alliances:**

- ❖ Renewable energies production. Remainders. Biofuel production.
- ❖ Residual, industrial and urban water purification. Biorremediation.
- ❖ Functional food and nutrition-health. New active biomolecules.
- ❖ Nourishing industry.
- ❖ Security and microbiological control.
- ❖ Projects of I+D+i in cooperation

### Contact

Av.Innovación 1. Edificio BIC.  
Parque Tecnológico Ciencias de la Salud.  
Armillá - 18100 Granada

Tel.: +34 958 750 618  
Fax: + 34 958 301 477  
[www.biot.es](http://www.biot.es)

**Agustín Lasserrot**  
General Director  
[direccion@biot.es](mailto:direccion@biot.es)





## Who is Who?



Business Members

asebio

### Biotech Projects

## Biotech Projects

### Sector: Biotechnology

#### Mission:

- ❖ Biotech Projects is dedicated to creating and managing companies in the biotechnology sector.
- ❖ Biotech Projects main objective is to create companies which transform scientific research into marketable products.

**Products:** Biotech Projects provide the opportunity to transform scientific results into profitable companies. Biotech Projects provides business development and project management, with funding at each step. We collaborate with leading companies and research centres of excellence to transform innovative concepts into practical solutions.

**Interest areas for futures collaborations/alliances:** Scientific entrepreneurs. Investment .

#### Contact

Gran Via de les Corts  
Catalanes, 617  
Àtico 2ª  
Barcelona  
08007 Barcelona

Tel.: + 34 933 435 278  
Fax: + 34 933 014 341  
<http://www.biotech-projects.com>

#### Joan Trenchs

Business Development Manager  
[joan.trenchs@biotech-projects.com](mailto:joan.trenchs@biotech-projects.com)



## Biotechnet I+D, S.A.

### Sector: Human Health Care

#### Contact

Alpedrete, 20  
Madrid  
28045 Madrid

Tel.: + 34 914 680 800  
Fax: + 34 914 685 934

#### José Anduiza

Managing Director  
[pquintan@faes.es](mailto:pquintan@faes.es)



## BTI Biotechnology Institute

### Sector: Biotechnology and Human Health Care

**Mission:** Continued research and development of new bone regeneration products and techniques.

#### Products:

- ❖ Plasma rich in growth factors (PRGF).
- ❖ Surgical Devices.
- ❖ Research and development.
- ❖ Dental implants.
- ❖ Surgical and prosthetic instruments.
- ❖ Publisher of "Dental Dialogue".
- ❖ BTI Scan ( Diagnostic software for oral implants and oral surgery).
- ❖ Continuing in-service training centre.

**Interest areas for futures collaborations/alliances:** Tissue engineering and bone regeneration.

#### Contact

San Antonio, 15 -5ª Planta  
Vitoria  
01005 Alava

Tel.: + 34 945 140 024  
Fax: + 34 945 135 203  
<http://www.bti-implant.es>  
<http://www.prgf.net>

#### Dr. Eduardo Anitua Aldecoa

Scientific Affairs Manager  
[eduardo.anitua@bti-implant.es](mailto:eduardo.anitua@bti-implant.es)

## Biotherapix Molecular Medicines S.L.U.

### Sector: Biotechnology

**Mission:** Biotherapix Molecular Medicines S.L.U. is a company belonging to the Genetrix Group, which specialises in human antibodies and molecules derived from them.

Its activity centres of the generation of new therapeutic molecules based on antibodies for the treatment of infectious, degenerative and inflammatory diseases. Its technology platforms make it a company competitive in the development of therapeutic molecules of a biological origin.

**Interest areas for futures collaborations/alliances:** Molecular therapy. Protein biology. Protein production and purification systems. Development of therapeutic antibodies. Inflammation. Infectious diseases.

#### Contact

Pza de la Encina, 10-11.  
Núcleo 1, 3ª Planta.  
Tres Cantos  
28760 Madrid

Tel.: + 34 918 063 089  
Fax: + 34 918 063 090  
<http://www.biotherapix.com>

#### Juan Sebastián Ruiz

Institutional Relations Manager  
[jsruiz@genetrix.es](mailto:jsruiz@genetrix.es)



## Biotoools B&M Labs, S.A.

### Sector: Diagnostics and R&D

**Mission:** Development and commercialisation of innovating technologies and products aimed to provide the diagnostic, biomedical research and Agfood sectors with high quality and easy to use kits and reagents, positioning Biotoools as a leading player in the diagnostic market based upon Real Time DNA amplification techniques.

**Products:** Real Time Diagnostic Kits for Tuberculosis, Listeria, Legionella and other infectious diseases, molecular biology reagents (polymerases, Real Time Kits, agarose, markers, etc.), as well as Real Time KIts for detection of GMOs and identification of animal species. All our kits are based upon Biotoools own and patented LIONPROBES and GELIFICATION Technology platforms

**Interest areas for futures collaborations/alliances:** Desarrollo y comercialización de kits de diagnóstico; I+D biomédica (SNPs), etc.

#### Contact

Valle de Tobalina 52, nave 43  
Madrid  
28021 Madrid

Tel.: + 34 917 100 074  
Fax: + 34 915 053 118  
<http://www.biotoools.net>

#### Pedro M. Franco


CEO  
[pedro@biotoools.net](mailto:pedro@biotoools.net)







## Who is Who?



Business Members

asebio



## Blueline Advanced Services

### Sector: Consultancy

**Mission:** Blueline focuses on helping their clients discover and take advantages of growth opportunities given by innovation based on Science.

**Products:** Innovation strategic consultancy with a specialized division on Biotechnology and Life Sciences.

**Interest areas for futures collaborations/alliances:** The Biotechnology and Life Sciences division of Blueline develops its activities around the following areas:

- ❖ **Public Policies.** Blueline carries out projects oriented towards the design and implementation of public policies to support biotechnology and its application sectors (health, food, and environment) and elaborates programmes for creating technology-based companies.
- ❖ **R&D&I environment.** Support to Public Research Organisms, university institutes, science parks, technology centres, incubators and OTRIs (Offices for the Transfer of Research Results) in the development of their strategies (among others technology transfer, internationalization, Human Resources). Facilitation of research project management in collaboration with companies, and creation and coordination of R&D partnerships.
- ❖ **Business Development in biotechnology.** Blueline has a broad experience in the elaboration of business plans, investment consultancy, and evaluation of technologies and companies. Evaluation of the viability of biotechnology projects in the pharmaceutical, clinical, agrifood, energy, and environment sectors and in industrial processes. Planning of marketing and commercialization, and definition of intellectual and industrial property policies in biotechnology.

### Contact

Almagro, 3 - 6º  
Madrid  
E-28006 Madrid

Tel.: + 34 917 814 974 / 61  
Fax: + 34 914 354 076  
www.bluelinespain.com

**Jorge Arenas-Vidal**  
Director  
jarenas@bluelinespain.com



## Bosques Naturales, S.A.

### Sector: Environment

#### Mission:

- ❖ Promotion and maintenance of fine wood forestry plantations. This activity has a triple function: Sustainability, Productivity and Innovation.
- ❖ Bosques Naturales is a company leading research and development which applies vegetal biotechnology and intensive agronomic techniques to its production processes. Its lines of research in forestry biotechnology are oriented to genetic characterization of vegetal material in order to improve the volume and quality of wood.

#### Products:

- ❖ Plantations of high economic value trees using selected vegetal material which is reproduced in vitro.
- ❖ The company has a Vegetal Tissue Growth Unit which provides its own germplasm bank.

**Services:** Bosques Naturales covers all the growth and maintenance costs of the trees during the twenty or twenty-five years which their productive cycle lasts.

#### Contact

Avda. de la Vega, 1  
Edificio 3  
Alcobendas  
28108 Madrid

Tel.: 913 604 200  
Fax: 913 604 201  
http://www.bosquesnaturales.com

**Teresa Jiménez**  
Communication Manager  
teresajimenez@bosquesnaturales.com

## Bristol- Myers Squibb, S.L.



### Sector: Health Care

**Mission:** To improve and prolong human life by marketing drugs of the highest quality and healthcare products.

**Products:** Drugs and other products in the following therapeutic areas: Cancer, Cardiovascular/ metabolism, Nervous System, Pain, Infectious diseases, Antibiotics, Diagnostic imagery, Infant nutrition, Ostomy pouches, Artificial skin.

#### Contact

Almansa, 101  
Madrid  
28040 Madrid

Tel.: + 34 914 565 457  
Fax: + 34 914 565 501  
http://www.bms.com

**Concepción Serrano**  
Manager for Institutional Records and Relations  
concha.serrano@bms.com

## Calantia Biotech, S.L.



### Sector: Bioenergy

**Mission:** Calantia Biotech was created in 2005. Its mission is to contribute to the efficiency of the energy sector s processes by means of biotechnological approaches. Although the development of specific scientific competencies is necessary for this purpose, the company also has the ability to imagine, feel and create new solutions.

**Services:** Calantia Biotech does avant-garde research aimed at eliminating the technological barriers of the bioenergy sector, and at improving the productivity of each step of the biofuels generation process through:

- The identification and selection of non-traditional crops with high energy potential.
- The implementation and genetic improvement of bioenergy crops (resistance to drought, fungus and virus, among others).
- The enhancement of the processes to obtain biofuels (degradation of cellulose, among others).
- The exploitation of industrial residues proceeding from these processes (biotransformation into products with increasing demand in other sectors): development of the overall concept of biorefinery.

#### Contact

CEEI Valencia Parque Tecnológico  
Avda. Benjamín Franklin, 12  
Paterna  
46980 Valencia

Tel.: + 34 961 994 233  
Fax: + 34 961 994 220  
http://www.calantia.com

**Mamen Lladró**  
CEO  
mlladro@calantia.com



## Who is Who?



Business Members

asebio



## Canvax Biotech S.L.

**Sector:** Human Health Care

**Mission:** The search for antigens for vaccines.

**Products:** Own technology for the identification of antigens inducing T CD4+ and CD8+ response.

**Interest areas for futures colaborations/alliances:** Vaccine sector, model animals for protection against infections.

**Contact**

CL Alcalde Velasco Navarro 10, 5-lzq  
Córdoba  
14004 Córdoba

Tel.: + 34 957 420 870  
Fax: + 34 957 421 792

**Elier Paz Rojas**  
Managing Director  
e.paz@dominion.es



## Ceifer, S.L.

**Sector:** Assisted Reproduction Centres

**Mission:** Human fertility study and research

**Products:** Assisted reproduction techniques, freezing of human fertility cells.

**Contact**

Martínez Campos, 1. 1º A  
Granada  
18005 Granada

Tel.: + 34 958 254 112  
Fax: + 34 958 254 134  
http://www.ceifer.com

**Juan Pablo Ramírez López**  
General Manager  
info@ceifer.com



## Cellerix, S.A.

**Sector:** Biotechnology

**Mission:** Cellerix, SA is a biopharmaceutical company, that was spun off from Genetrix in 2004. Cellerix is specialized in the clinical development of cell therapies. The products developed by the Company are living medicines that act upon the body in a natural manner thanks to the therapeutic potential of adult stem cells. At present, the company has two products in clinical stage development (one of which is now in a phase III clinical trial), as well as several preclinical stage programmes.

**Products:**

- ❖ **Ontaril®** is Cellerix' proposal for the treatment of complex perianal fistulas. Ontaril® contains stem cells obtained from adipose tissue of the patient and is currently undergoing phase III clinical evaluation. Ontaril® has been designated an Orphan Drug status by EMEA
- ❖ **Cx501** is Cellerix' proposal for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). Epidermolysis Bullosa is a rare hereditary disease in which lack of collagen VII prevents the skin adhering to the base membrane, therefore causing serious lesions at the slightest friction. Cx501 is a chimeric skin equivalent that is currently undergoing a Phase II/III clinical trial. Cx501 has been designated an Orphan Drug by EMEA.
- ❖ Allogeneic Development is comprised in the **Cx601** and **Cx611** programmes, which take advantage of the intrinsic properties of eASCs.
- ❖ **Cx601** is based on the local delivery of eASCs, and is expected to start clinical evaluation in 2008. Cx611 is based on the systemic delivery of eASCs and will be developed to target larger autoimmune diseases.

**Interest areas for futures colaborations/alliances:** Cell therapy, Regenerative medicine, Tissue engineering, Cell medicines, Regulatory issues concerning cell therapy.

**Contact**

Marconi, 1  
Tres Cantos  
28760 Madrid

Tel.: + 34 918 049 264  
Fax: + 34 918 049 263  
http://www.cellerix.com

**María Pascual**  
mpascual@cellerix.com

## Chimera Pharma, S.L.U.

**Sector:** Biotechnology and Immunotherapy

**Mission:** Development of immunotherapeutic vaccines against major indications in human health (infectious disease, cancer y cardiovascular).

**Products:** niversal influenza vaccine - Preclinical, Therapeutic cervical cancer vaccine- Preclinical, Lung cancer vaccine - R&D, Cardiovascular vaccine - R&D.

**Interest areas for futures colaborations/alliances:** Looking to establish collaboration with companies and research institutions with extracellular (cell bound or soluble) therapeutic targets relevant to human disease and susceptible to immunotherapeutic approaches.

**Contact**

Ronda de Poniente, 4  
Bajo C-D  
Tres Cantos  
28760 Madrid

Tel.: + 34 911 417 150  
Fax: + 34 911 417 151  
www.chimera-pharma.com

**Arcadio García de Castro**  
Business Development Manager  
agarcia@bionostra.com



## Clean Biotec

**Sector:** Environmental Biotechnology

**Mission:**

- ❖ Find solutions to resolve environmental pollution problems using clean, sustainable and economical technologies.
- ❖ Improve the natural regulation capacity of ecosystems to reduce environmental impacts.
- ❖ New ways of natural and controlled systems for waste elimination and recycling.

**Products:** Ecodiagnostics, Environmental audit reports, Waste assesment projects, Paleobotanic studies, Implantation and control of biomonitoring networks, Phytoremediation and Bioremediation, R & D biorremediation projects, Restoration of degraded lands, Reseach and improvement of new phyto and bioremediators, Microorganism research from extreme environments to use in bioremediation and other biotechnological applications.

**Interest areas for futures colaborations/alliances:** Environmental microbiology, Bioremediation, Biomonitoring, Metagenomics.

**Contact**

San José De Calasanz 11 Bajo  
La Rioja  
26004 Logroño

Tel.: + 34 941 238 261  
Fax: + 34 941 238 261  
http://www.clean-biotec.com

**Nathalie Beaucourt**  
R&D Manager  
nathalie@clean-biotec.com



## CPQ Ingenieros S.L.

**Sector:** Pharmaceutical and biopharmaceutical engineering

**Mission:** CPQPharma division s prime objective is to provide highly professional consultancy, process and detail engineering and supervision services for the industrial projects of pharmaceutical and biopharmaceutical companies.

**Services:** Basic and detail engineering and supervision for pharmaceutical and biopharmaceutical companies. Pilot Plant design. Process and bioprocess scale-up. Cost Estimation of biopharmaceutical facilities.

**Áreas de interés para futuras colaboraciones:** Pharmaceutical and Biopharmaceutical Industrial installations, Cost Estimation of Biopharmaceutical Industrial Installations, Pilot Plant Design, Process and Bioprocess Scale-Up, Industrial Biotechnology, Industrial Nanotechnology.

**Contact**

Gran Vía de les Corts Catalanes  
751 A 1º 2ª  
Barcelona

Tel.: 932 478 830  
Fax: 932 478 833  
http://www.cpqingenieros.com

**Ricard Gené**  
Technical Manager  
rgene@cpqingenieros.com





## Who is Who?



## Digna Biotech, S.L.

### Sector: Biotechnology

**Mission:** To give value to the research undertaken in the CIMA (University of Navarre Applied Medical Research Centre) by means of preclinical and clinical development of the intellectual property generated by the researchers there.

### Products:

**Under development:** TGF-B1, IFN.

**In the Pipeline:** Cardiotrophin, Anti-EPCR, SnRNPUmod, Ad/SFV, Early diagnosis of hepatocarcinoma, Anfirregulina in acute hepatic diseases.

### Contact

Boix y Morer, 6, 8º  
Madrid  
28003 Madrid

Tel.: + 34 911 852 510  
Fax: + 34 911 852 519  
<http://www.dignabiotech.com>

### Maite Soria

Managerial Secretary  
[msoria@dignabiotech.com](mailto:msoria@dignabiotech.com)



## Dracena Bioresearch Canarias S.L.

### Sector: Biomedicine

### Mission:

- ❖ To establish competitive alliances with research and industry for new molecule development.
- ❖ To consolidate the undertaking of clinical trials in the Canary Isles.
- ❖ In the medium term, our objective is to manage clinical studies of the highest quality and efficiency in Latin America.

**Services:** CRO + Full Service. Strategic alliances and co-development projects. Specialised consultancy in Biomedicine. Clinical studies phases II, III and IV. On-site monitors. Without travelling or subsidence expenses. Time savings in management and monitoring. Better attention and direct contact with researchers. Network of contacts with managers, administrators and research units. Strategic alliances and co-development projects. Clinical studies and financing solutions for the development of molecules discovered by hospitals, universities and research centres. Contact bridge between industry and research centres, universities and hospitals. Consultancy in the Biomedical Sector. Scientific, regulatory and administrative advisory services for clinical studies. Medical marketing advisory services in a variety of therapy areas. Networking with opinion leaders and researchers at a national and international level. Organisation of medical and scientific training days and events. Advisory services for the settlement of biotech companies in the low taxation area of the Canary isles.

### Interest areas for futures collaborations/alliances:

- ❖ Development of clinical trials and settlement of biotech companies in the Canary Isles.
- ❖ Clinical studies and financing solutions for the development of molecules discovered by hospitals, universities and research centres.
- ❖ Undertaking drug and economic projects.
- ❖ Contact bridge between industry and research centres, universities and hospitals.

### Contact

Ed. Central Parque Tecnológico, Planta Baja, Oficina 11, Campus de Tafira  
Tafira, Las Palmas  
35017 Las Palmas

Tel.: 928 457 305  
Fax: 928 457 088  
<http://www.dracenabioresearch.com>

### Carmelo González

General Manager  
[cgonzalez@dracenabio.com](mailto:cgonzalez@dracenabio.com)



Business Members

asebio

## Engineering for Business, WT (E4b)

### Sector: Engineering

**Mission:** E4b has served the pharmaceutical industry for years contributing to its technological development and efficiency. We offer Turn-key Projects, basic and detailed engineering, Project Management and execution of industrial installations.

**Services:** Legal framework for the different installations. Site projects. Architecture. Structure calculation. Consultancy. Process engineering. Industrial infrastructures: electrical, air conditioning, fire protection systems, renewable power, natural gas, heating, etc. Emergency plans. Refurbishment of premises. External engineering services (technical drawing, preventive maintenance). Detailed engineering. Technical drawing. Technical training (Fire Protection System, Safety Rules at Work Site, etc.).

**Interest areas for futures collaborations/alliances:** I+D+i, International Projects, global designing.

### Contact

Calle López de Hoyos 342 C  
Madrid  
28043 Madrid

Tel.: 915 769 964  
Fax: 915 764 170  
<http://www.eforb.com>

### Germán Hernando

Manager  
[german@eforb.com](mailto:german@eforb.com)



## EntreChem, S.L.

### Sector: Human Health, Drug Discovery

**Mission:** Our objective is the discovery and development of bioactive new chemical entities (NCEs) from microbial natural products. We generate novel analogs by combinatorial biosynthesis of the corresponding metabolic pathways, identify the most promising candidates and advanced the preclinical development until demonstration of efficacy in vivo.

**Products:** EntreChem offers genetic engineering for identification and manipulation of metabolic pathways from bacterial natural products of interest in the pharmaceutical (antibiotics, antitumorals, antifungals) and agro (insecticides, herbicides) sectors. EntreChem offers enantiopure products for medicinal chemistry and services of applied biocatalysis, as well as custom synthesis of optically pure compounds.

### Interest areas for futures collaborations/alliances:

- ❖ Discovery and development of new drugs from natural products by genetic engineering and biocatalysis. Antitumor and antitumor activity assays (cellular and biochemical), target identification.
- ❖ Early preclinical - in vivo - studies (efficacy, PK).
- ❖ Bioprocess scale-up.

### Contact

Edificio Científico Tecnológico, Campus "El Cristo"  
Oviedo  
33006 Asturias

Tel.: + 34 985 259021  
Fax: + 34 985 103686  
[www.entrechem.com](http://www.entrechem.com)

### Francisco Morís

Co-founder & CEO  
[info@entrechem.com](mailto:info@entrechem.com)







## Who is Who?



Business Members

asebio



## Era7 Information Technologies, S.L.

### Sector: Bioinformatics

**Mission:** To help biotech companies and organizations in the biomedical field to take advantage of Information Technologies for a better information and knowledge management. With this objective in mind we design and provide advanced software solutions specially based on Internet technologies.

### Products:

- ❖ **Palinsight Pro:** Software for DNA palindromicity analysis and representation.
- ❖ **Livera7:** Software specially designed to manage and held real time virtual Congresses and workshops.

**Services:** Services of Knowledge Expression. Services of custom software development of Web applications, intranets, Web platforms and bioinformatics workflows automation. Bioinformatics and biosciences consultancy services.

**Interest areas for futures colaborations/alliances:** Bioinformatics software development. Participation in R&D and innovation projects including participation in the EU VII Framework Program. Agreements for marketing and distribution of our services and products.

### Contact

BIC Granada  
Avenida de la Innovación 1  
Parque tecnológico Ciencias de la Salud  
Armillar - 18100 Granada

Tel.: + 34 958 750 629  
Fax: + 34 958 750 629  
<http://www.era7.com>

**Eduardo Pareja**  
General Manager  
[epareja@era7.com](mailto:epareja@era7.com)



## Esteve

### Sector: Pharmaceutical Industry

**Mission:** Esteve is an R&D oriented company with a commitment to provide society with new therapeutic solutions with a high innovating value.

**Products:** Esteve's activity lies in the pharmaceutical field, where it undertakes the research and development of new drugs in the area of prescription products, pharmaceutical advertising specialities, Vaccines, Hospital and Veterinary products, together with the production of drug active components.

### Contact

Av. Mare de Déu de Montserrat, 221  
Barcelona  
08041 Barcelona

Tel.: + 34 934 466 000  
Fax: + 34 934 504 899  
<http://www.esteve.com>

**Dr. Eduard Valentí**  
R&D Operations Manager  
[evalenti@esteve.es](mailto:evalenti@esteve.es)



## EuroGalenus Executive Search

### Sector: Executive Search Consultants

**Mission:** Contribute to the identification and development of the best executives in the Biotechnology field.

**Services:** Since 1992, recruitment of Board positions, non-executive Directors and senior Scientists. Experience in Biotechnology, Diagnostics, Devices, Electromedicine, Pharmaceuticals, Nutrition, Cosmetics, Veterinary, and their Service companies.

**Interest areas for futures colaborations/alliances:** Recruitment, training, HR consultancy.

### Contact

Avda. Alberto Alcocer, 7  
Madrid  
28036 Madrid

Tel.: + 34 913 505 556 / 7414  
Fax: + 34 913 507 415  
[www.eurogalenus.com](http://www.eurogalenus.com)

**Luis Truchado**  
Partner-Director  
[informacion@eurogalenus.com](mailto:informacion@eurogalenus.com)

## Eurosemillas, S.A.



### Sector: Agriculture, Agrifoodstuffs Industry

**Mission:** To be a company of reference in the farming world, committed to agricultural development in the geographical areas where it is present.

**Products:** Select seeds. CottonGrain: cotton grain animal feed. Cotton fibre. Oleaginous oils.

**Development of licences for various plants:** Fruit trees. Strawberry. Citrus fruits. Raspberry.

**Others:** avocado pears, asparagus, etc.

**Services:** Farming news portal <http://terraagraria.es>. Development of an electronic commerce platform.

**Interest areas for futures colaborations/alliances:** Select seeds. Genetic improvement Biotechnology. Development of plant varieties. Farming portal. Extraction of vegetable oils and cotton fibre.

### Contact

Paseo de la Victoria, 31 1º A  
Córdoba  
14004 Córdoba

Tel.: + 34 957 421 732  
Fax: + 34 957 422 092  
<http://www.eurosemillas.com>

**José Pellicer**  
Development Manager  
[eurosemillas@eurosemillas.com](mailto:eurosemillas@eurosemillas.com)

## Exxentia, Grupo Fitoterapeutico



### Sector: Bio active ingredients for the food and pharmaceutical industries.

**Mission:** Convert ourselves into a reference for our clients in product development based on natural extracts, lipids and probiotics.

**Products:** Vegetable, lipid and probiotic extracts, exclusive product development, technical and legal consultants, regulatory affairs, stability studies.

**Interest areas for futures colaborations/alliances:** Development of new bio active ingredients based on vegetable, lipid and probiotics extracts and their application in the pharmaceutical, food and cosmetic industries.

### Contact

C/ González Dávila, 18, 6º Pl.  
Madrid  
28031 Madrid

Tel.: + 34 913 802 973  
Fax: + 34 913 802 279  
<http://www.exxentia.com>

**José Carlos Quintela**  
Scientific Director  
[jcquintela@exxentia.com](mailto:jcquintela@exxentia.com)



## Who is Who?



## Farm Biocontrol, S.L.

**Sector:** Livestock farming, Agro-feeding and Environment

**Mission:** The commitment between Farm Biocontrol and the R+D inside the environmental frame, has leads us to be part of CDTI programme which is promoted by the Industry and Commerce Ministry of the Spanish Government.

Farm Biocontrol offers complete services of consultancy, assistance and implementation of integral plans in order to reach a biosanitary control in livestock farms. Our mission is provided with the highest biosafety level to pig, cattle, poultry and fish farms. The enormous scientific team who supports us, allows to reach this aim focusing our efforts fundamentally in two work areas:

- ❖ Research, development, production and marketing of new products such as pesticides, biological disinfectants, products for the animal hygiene, as well as procedures of application. Applicable to waters, atmospheres, surfaces or directly over animals.

- ❖ Development of integral and personalized programmes of biosafety in livestock farms.

Our entailment with the academic World, has leaded us to be accredited as an European Approved Training Centre in order to train to a many professionals linked to the live stocking, agro-feeding and environmental sector.

**Products:** Expert Consultancy and elaboration of reports and Action Plans. Systems to the slurry treatment. Systems to the gas emission reduction. Pest Control. Waters and Effluents Control. Salmonella Control. Laboratory Analysis. Training for technicians, managers and staff. Hazard Identification and Analysis of Critical Control Points.

**Interest areas for futures colaborations/alliances:** Biotechnology. Biosafety and hygiene. Food traceability. Agriculture. Farms disinfection. Water treatment. Food Industry. Fish farms.

**Contact**

Polígono Industrial Valdeferrín, Nave 7  
Ejea de los Caballeros  
50600 Zaragoza

Tel.: + 34 976 660 114  
Fax: + 34 976 661 149

**Nuria Porras**  
Manager Director  
internacional@farmbiocontrol.com  
**Rafael Arlegui**  
Manager Director  
r.arlegui@farmbiocontrol.com



## Fina Biotech, S.L.

**Sector:** Biotechnology

**Mission:** The search for kits for diagnosis, prognosis and/ or response to cancer treatment, to cardiovascular and neurodegenerative diseases and others.

Therapy with adult stem cells.

Licence or sale of products resulting from research to interested companies.

**Products:**

- ❖ **HALOSPERM**®, a kit for the diagnosis of male fertility based on DNA fragmentation.

- ❖ **F12**®, kit for genetic risk of thrombosis.

**Contact**

Camino de las Huertas, 2  
Edificio INDAS  
Pozuelo de Alarcón  
Madrid

Tel.: + 34 917 991 564  
Fax: + 34 913 517 118

**José-Cándido Arochena Amestoy**  
General Manager  
Jc\_aroचना@finabiotech.es



Business Members

asebio

## Genetrix, S.L.

**Sector:** Biotechnology

**Mission:** Genetrix is one of a group of biotech companies specialised in the biomedicine area, born with the mission of fostering leading biopharmaceutical initiatives in the sector. The company's main objective is to incorporate the outcomes of academic research into Medicine.

**Services:**

- ❖ Genetrix is constantly working to bring together the outcomes arising from different scientific disciplines, by setting up and maintaining collaborations of a varied nature with public research centres, technological centres, public and private hospitals and pharmaceutical and biotech enterprises. This collaborative spirit is one of the features that most identifies the Genetrix Group and its has proven to be of great value in making this ambitious business project a reality. The Group is working on the creation of biotech initiatives assessing, designing and executing business plans in the life sciences field.

- ❖ The rapid evolution of the Genetrix Group is the direct result of the excellent quality of the work carried out by its professionals and the special concept held by its development team of the biotech business. The group's speed of development is also underpinned by the selection of staff from a scientific and business background, in the keeping up of the links and collaboration with a variety of groups and the appointment of professionals of the highest level onto its management team.

**Interest areas for futures colaborations/alliances:**

- ❖ Biotechnology.

- ❖ Life Sciences.

- ❖ Scientific applications for medical purposes.

- ❖ Investment in biotechnology.

**Contact**

Pza de la Encina, 10-11. Núcleo 1,  
3ª Planta.  
Tres Cantos  
28760 Madrid

Tel.: + 34 918 063 089  
Fax: + 34 918 063 090  
<http://www.biotherapix.com>

**Juan Sebastián Ruiz**  
Institutional Relations Director  
jsruiz@genetrix.es



## Genomica, S.A.U.

**Sector:** Human Health Care

**Mission:** To offer experience and quality in all its products and services. To provide the health system with a tool for differential clinical molecular diagnosis applicable to infectious and oncogenic diseases. To be a reference centre in Spain for genetic identification tests, working under an accreditation frame provided by ENAC.

**Products:** Molecular diagnostic kits focused on infectious and oncogenic diseases.

**Services:** Human DNA identification tests. Forensic Genetics technology transfer by Turn key projects : design, assembling of the laboratory, training of personnel, technical service and population database creation. Using genomics and proteomics tools, systems are being prepared to detect therapeutic activity in marine organisms for different diseases.

**Interest areas for futures colaborations/alliances:**

**In licensing:** Oncology molecular diagnostic systems. New molecular diagnostic technologies.

**Out licensing:** Technology transfer and training in forensic genetics.

**Contact**

Alcarria nº 7 Edificio Zeltia  
Coslada  
28820 Madrid

Tel.: + 34 916 748 990  
Fax: + 34 916 748 991  
<http://www.genomica.es>

**Rosario Cospedal**  
General Manager  
rcospedal@genomica.es





## Who is Who?



## Genzyme, S.L.

**Sector:** Human Health Care

**Mission:**

- ❖ The discovery and development of innovating products and services for the treatment of serious pathologies, with special attention to rare diseases.
- ❖ Genzyme S.L. is the subsidiary of Genzyme Corporation in Spain, dedicated to the development and introduction of therapeutic solutions for unresolved medical problems.

**Products:**

Products on the market and under development at the following stages:

- Lysosomal diseases: **Cerezyme®**, **Fabrazyme®**, **Aldurazyme®**
- Renal insufficiency: **Renagel®**
- Cancer: **Thyrogen®**
- Transplants: **Thymoglobulina®**
- Immunological disorders
- Neurodegenerative diseases
- Articular viscosupplementation: **Synvisc®**
- Surgical adhesions: **Seprafilm®**
- Biomaterials
- Disease Pompe: **Myozyme®**

**Services:** Cell therapies.

**Interest areas for futures collaborations/alliances:**

- ❖ Rare diseases.
- ❖ Orphan medical.
- ❖ Renal insufficiency.
- ❖ Oncology.

**Contact**

Damián Sánchez López, 3  
San Sebastián de los Reyes  
28703 Madrid

Tel.: + 34 916 591 670  
Fax: + 34 916 596 862  
<http://www.genzyme.com>

**Fernando Royo**  
CEO

[genzymespain@genzyme.com](mailto:genzymespain@genzyme.com)



## Gilead Sciences, S.L.

**Sector:** Human Health

**Mission:** Investigate, Develop and commercialize innovative drugs in therapeutics areas with uncover needs, with the objective to improve curation and surveillance rates in patients with severe infectious diseases.

**Products:** VIH: Viread® (tenofovir disoproxil), Emtriva® (emtricitabina), Truvada® (tenofovir disoproxil y emtricitabina). Hepatitis B: Hepsera® (adefovir dipivoxil). Antifúngicos: AmBiso-me® (anfotericina B liposomal).

**Interest areas for futures collaborations/alliances:** Cardiovascular Area Respiratory Area.

**Contact**

C/ Agustín de Foxa, 27 Planta 11  
Madrid  
28036 Madrid

Tel.: + 34 913 789 830  
Fax: + 34 913 789 841  
<http://www.gilead.com>

**Roberto Urbez Plasencia**  
General Manager  
[roberto.urbez@gilead.com](mailto:roberto.urbez@gilead.com)



Business Members

asebio

## Grifols Engineering S.A.

**Sector:** Biopharmaceutical Engineering

**Mission:** The company belongs to the Grifols holding and is specialized in engineering and consultancy services for the biotechnological and pharmaceutical fields.

Grifols Engineering s objective is to become the appropriate collaborator for the scale-up of the biotech field companies, from development phases to industrial production.

**Products:** Services of Biopharmaceutical Engineering and Consultany. **Machinery for biotechnological process:** Fermentation, purification and aseptic filling. Prototypes of machinery for biotechnological processes.

**Interest areas for futures collaborations/alliances:** Biotechnology. Technological applications for medical purposes.

**Contact**

C/ Can Guasch, 2  
Parets del Valles  
E-08150 Barcelona

Tel.: + 34 935 710 393  
Fax: + 34 935 710 393  
<http://www.grifolsengineering.com>

**Oriol Argemi**  
Business Unit Development Mg.  
[oriol.argemi@grifols.com](mailto:oriol.argemi@grifols.com)



## Histocell, S.L.

**Sector:** Tissue Engineering and Cell Therapy

**Mission:** Histocell is a biotechnology company that offers to the bio sanitary sector innovative products based on human osteoblast, chondrocytes, keratinocytes, fibroblast and mesenchymal stem cells for tissue regeneration. These cell products will be applied to different pathologies in the regenerative medicine area. Histocell is also a research company involved in many R&D projects to develop an innovative pipeline of new health products for tissue engineering and cell therapy.

**Services:** Development of new biological drugs based on stem cells for human regenerative medicine. Tissue Engineering: Histocell has a Clean Room that allows to develop innovative products for clinical use in optimum quality conditions. Biological research services: cell amplification, cell metabolism, growth factors detection and cell cytometry, among other services. We also offer personalized tests to satisfy our customer needs. In vitro biocompatibility tests of materials for biomedical uses.

**Interest areas for futures collaborations/alliances:** Histocell is a company with a great growth potential in next years. In next future, Histocell will open new research lines that solve the possible lacks existing in other regenerative medicine and cell therapy areas. Our company will also provide new cell/tissue products that will improve pharmaceutical and/or cosmetic testing of new cosmetics or new drugs. The company is interested in alliances with companies or research groups specialised in developing new biomaterials for tissue engineering.

**Contact**

Parque Tecnológico de Bizkaia,  
Edificio 800, 2ª planta  
Derio  
48160 Bizkaia

Tel.: + 34 946 567 900  
Fax: + 34 944 036 999

**Marta Acilú**  
Business Development Manager  
[acilu@histocell.com](mailto:acilu@histocell.com)







## Who is Who?



## Imbiosis, S.L.

**Sector:** Biotechnology

**Mission:** Imbiosis, S.L. is a spin-off company, founded out of the Gluten Unit of the National Centre for Biotechnology (CNB), in which Genetrix, S.L. holds a 100% shareholding. It was founded with the commitment to develop new forms of food diagnostics, to assure the celiac community the supply of the only effective treatment for their disease: gluten-free food products. Imbiosis S.L. has set itself the target of becoming a leading biotech company in the analysis and traceability of gluten in foodstuffs.

**Products:** Extraction Cocktail.

**Services:**

**Quantitative techniques available:** ELISA R5. Competitive ELISA R5.

**Qualitative techniques available:** Western bolt. PCR RT. Maldi Tof

**Áreas de interés para futuras colaboraciones:** Diagnóstico y trazabilidad alimentaria

**Contact**

Pza de la Encina, 10-11.  
Núcleo 1, 3ª Planta.  
Tres Cantos  
28760 Madrid

Tel.: + 34 918 063 089  
Fax: + 34 918 063 090  
www.biotherapix.com

**Juan Sebastián Ruiz**  
Institutional Relations Director  
jsruiz@genetrix.es



## Infociencia

**Sector:** Contract Research Organization

**Mission:** Infociencia is a full-service clinical Contract Research Organisation (CRO) dedicated to the clinical drug development process of new molecular entities. We provide clinical trials from Phase I to Registration and Phase IV. Our mission is to deliver the highest level of quality, experience and care to the clinical trials of the Biotech, Diagnostics and Pharma Companies. Infociencia operates in Spain, and all over Europe and former Soviet Republics via its associate company IMITIS (www.imitis.com).

**Services:** We provide clinical operations in Spain and Europe for the development of the Clinical Trials Program of new drugs, from Phase I to Registration and Phase IV.

The detailed services are: Expert assistance in the elaboration of the Clinical Development Plan of the new drug. Phase I units (Spain, France and Bulgaria). Clinical trials from Phase II to Phase III, Registration and Phase IV. Study Protocol development. Regulatory and Authorization in Europe. Monitoring and Project Management. Quality Assurance and Audit of Clinical Trials. Data Management and Biostatistics. Medical Writing (Clinical Reports, Scientific Articles,). EMEA Registry and CE Marking Authorization. Electronic Data Capture.

**Interest areas for futures colaborations/alliances:** We can help Biotech and Diagnostic companies to conduct the clinical trials necessary for the product marketing authorization. We have experience in clinical trials, from the design of the clinical plan to the Phase I to Phase III, Registration, and Phase IV trials. We can help Biotech and Diagnostic companies to obtain the EMEA marketing authorization or the CE Marking. We can conduct clinical trials in all Europe and former Soviet Republics.

**Contact**

Balmes 86 Pral  
Barcelona  
08023 Barcelona

Tel.: 932 158 008  
Fax: 932 158 016  
www.infociencia.com

**Jordi Naval**  
Managing Director  
Jordi.naval@infociencia.com



Business Members

asebio

## Immunology and Applied Genetics, S.A. INGENASA



**Sector:** Biotechnology in Animal Health Care

**Mission:** Research, development, production and commercialisation of biotech products for animal health care.

**Products:** Serologic diagnosis assays. Molecular diagnosis assays. Second generation vaccines.

**Services:** Protein expression, monoclonal antibodies.

**Contact**

Hermanos García Noblejas, 39. 8º  
Madrid  
28037 Madrid

Tel.: + 34 913 680 501  
Fax: + 34 914 087 598  
http://www.ingenasa.es

**Carmen Vela Olmo**  
General Manager  
cvela@ingenasa.es

## Innofood I+D+I S.L.

**Sector:** Biotechnology and Food Technology

**Mission:** INNOFOOD I+D+I S.L. is a spin-off create to improve the research and technological development of the food industry through the benefit of services and projects of R&D to the industry and whose application will be as much to ingredients as to food products, obtaining with it the increase of the productiveness and quality, improves of the client competitiveness.

**Services:** Assays and Improvement of food products shelf life. Design and development of new ingredients and foods. Special product design (functional, nutraceutical&). Conventional products redesign. Improvement of sensorial characteristics and commercialization. Application of new technologies to the elaboration of new foods (production systems, preservation, packaging...). Development of new functional and bio-ingredients from by-products.

**Interest areas for futures colaborations/alliances:** We offer the know-how in ingredients and products development and their application in different foods. Collaboration or joint-venture to work together in this field. Functional foods and functional ingredients. Projects about by-products from agrofood industry. Food biotechnology.

**Contact**

Parque Tecnológico de Ciencias  
de la Salud BIC Granada.  
Avda. Innovacion, 1  
Armilla - Granada

Tel.: + 34 958 750 607  
Fax: + 34 958 750 580

**Jose Maria Fernandez Gines**  
General Manager  
jmfernandez@innofood-idi.com





## Who is Who?



Business Members

asebio



## Institut Univ. de Ciència i Tecnologia, S.A. (IUCT)

### Sector: Research and Development

**Mission:** The mission of IUCT is to make use of its knowledge, expertise and capabilities to generate new technologies, products and processes for its industrial application in the Chemical, Pharmaceutical, Biotechnological and Environmental fields.

**Products:** IUCT has a large pipeline of products, processes and technologies available due to the development of its own R&D programmes to be transferred to the industry in the following areas:

1. Drug Discovery. 2. Industrial Biotechnology. 3. Drug Development. 4. Química Verde

The development of this research projects led to IUCT to the creation of its own Technology Platforms available for its use in industrial projects. These IUCT Technology Platforms are: Industrial Biotechnology, Sustainable Chemistry, Drug Discovery, High Throughput Analysis, Optimization of the Chemical Processes and Drug Development.

**Services:** Research, Development and Innovation projects under contract (Contract Research). IUCT has the capabilities to carry out contract research services taking into account viability and economic factors providing high-tech solutions at highly competitive prices. Technological services (Analysis and Consultancy): Services of analysis in different scientific areas making use of any of their laboratories of synthesis, physic-chemical, and microbiology analysis and its GMP complacence pharmaceutical pilot plant. Transfer of knowledge and specialised training: Open and customised training in broad areas of scientific knowledge. Organization of seminars, workshops and congresses.

**Interest areas for futures colaborations/alliances:** Pharmaceutical, biopharmaceutical and cosmetic sector. Chemical industry and fine chemical. Food industry. Environmental/ Health at work.

### Contact

C/ Alvarez de Castro, 63  
Mollet  
08100 Barcelona

Tel.: + 34 935 793 432  
Fax: + 34 935 705 745  
<http://www.iuct.com>

### Angeles Molina

Manager of the Business Projects Dept.  
[iuct.sales@iuct.com](mailto:iuct.sales@iuct.com)



## Instituto Biomar, S.L.

### Sector: Human Health Care

**Mission:** The discovery of new drugs of natural origin.

### Products:

- ❖ Microbial marine extracts.
- ❖ Compounds of scientific or industrial interest, of microbial origin.

### Services:

- ❖ Fermentation.
- ❖ Chemistry of natural products.
- ❖ Bioassays.
- ❖ Research programmes.

**Interest areas for futures colaborations/alliances:** Pharmaceutical and agrifoodstuff companies interested in the search for new bioactive principles of marine microbial origin. The company offers classified marine bacterial extracts, the undertaking of assays, fractioning, purification and structural elucidation of the active compounds. Production, up to kilos, of these for development studies.

### Contact

Edificio CEEI  
Polígono Industrial Onzonilla  
Onzonilla  
24231 León

Tel: + 34 987 849 200 / 913 860 159  
Fax: + 34 987 849 203  
<http://www.institutobiomar.com>

### Agustín Pérez-Aranda

General Manager  
[agustin@institutobiomar.com](mailto:agustin@institutobiomar.com)

## Integromics, S.L.



### Sector: Bio Information Technology

**Mission:** To provide the market with up to date knowledge on IT solutions in the field of life sciences and particularly in genomics and proteomics.

### Services:

- ❖ The development and marketing of software for genomic and proteomic data management, analysis and mining.
- ❖ Professional services relating to these products.

**Interest areas for futures colaborations/alliances:** The development and commercialisation of software for genomics, proteomics and related sectors.

### Contact

Avenida de la Innovación, 1  
Armilla  
18100 Granada

Tel.: + 34 958 750 627  
Fax: + 34 958 750 627  
<http://www.integromics.com>

### Vicente Rodríguez

Administrator  
[Vicente.rodriguez@integromics.com](mailto:Vicente.rodriguez@integromics.com)

## Intelligent Pharma



### Sector: Bioinformatics and Computational Chemistry

**Mission:** Intelligent Pharma is a unique and innovative computational solution provider focused on drug design and target validation. Intelligent Pharma develops customized and highly-specialized computational solutions for our clients in order to reduce their costs, time and/or risks in their molecular research projects.

### Services:

In early research stages we offer the following areas of expertise:

- ❖ Computer-aided drug design
- ❖ Molecular modeling
- ❖ Virtual screening
- ❖ Compound library management and intelligent accessory tools.
- ❖ ADME/Tox modeling
- ❖ Knowledge extraction and data mining from chemical and biologic databases
- ❖ Biologic image processing
- ❖ Improved/enhanced supercomputational research infrastructure

**Interest areas for futures colaborations/alliances:** Drug discovery.

### Contact

Parc Científic de Barcelona  
c/Baldiri Reixac, 10  
Barcelona  
08028 Barcelona

Tel.: + 34 934 034 551  
Fax: + 34 934 034 551  
[www.intelligentpharma.com](http://www.intelligentpharma.com)


### Ignasi Belda

CEO  
[ibelda@intelligentpharma.com](mailto:ibelda@intelligentpharma.com)





## Who is Who?



Business Members

asebio



## Inteman, S.A.

**Sector:** Chemical-biological

**Mission:** Inteman SA is a company specializing in the research, development, production, and distribution of professional highly innovative products based on enzymes and microorganisms.

**Products:**

- ❖ Biodetergency cleaning products for institutions, industries and communities.
- ❖ Bacteria based products that produce enzymes and biosurfactants for cleaning and the treatment of industrial water including septic, drain line and grease trap.

**Interest areas for futures colaborations/alliances:**

- ❖ Selection of microorganism, identification and optimization of fermentation process parameters.
- ❖ Develop of products focus on the health & safety of end users based on enzymes and microorganisms.

**Contact**

Lermandabide 23  
(Parque Industrial de Jundiz)  
Vitoria-Gasteiz

Tel.: + 34 945 29 21 00  
Fax: + 34 945 29 03 27  
www.inteman.com

**Miguel Ángel Pérez Ortiz de Elguea**  
Technical manager  
maperez@inteman.com



## Juste, S.A.Q.F.

**Sector:** Pharmaceutical Industry

**Mission:** JUSTE, S.A.Q.F. is a company which researches, develops and distributes pharmaceutical products. JUSTE also has an outstanding R+D and industrial activity related to the generation and manufacture of soft-gel capsules.

**Products:** **The Therapeutics Division** commercializes prescription drugs for the three following Areas: Primary Care, Women's Health Care and Central Nervous System. **The Hospital Division** remains dedicated to the diagnosis within the radiology field. JUSTE has diversified its hospital diagnosis line taking part and acquiring new projects and products which incorporate innovative technologies on diagnosis, oncology and anesthesia.

**Interest areas for futures colaborations/alliances:** JUSTE maintains a continual interest in collaborating on development projects as well in establishing License agreements (exclusive licenses, co-marketing and/or co-promotion agreements) for Spain, Portugal, Central America and South America countries in the following therapeutic areas Primary Care, Women's Health Care and Central Nervous System and products for diagnosis and treatment aimed at hospitals. JUSTE is aware of the advances in biotechnology and considers very important the use of genetics for a personalized medicine. JUSTE commits itself in the innovative biotechnology industry with new products for clinical diagnosis.

**Contact**

J. Ignacio Luca de Tena, 8  
Madrid  
28027 Madrid

Tel.: + 34 917 248 2 00  
Fax: + 34 917 248 205  
www.juste.com

**Charo Guinea**  
Business Development  
roguinea@juste.net

## Labgenetics, S.L.



**Sector:** Human Health Care / Diagnostics

**Mission:** To carry out highly accurate and decisive genetic tests within a minimum response period. To apply the most advanced techniques to identify alterations in the DNA sequence related to the onset of the most prevalent hereditary diseases in Europe. To consolidate as the Reference Centre in Forensic Genetics and Human Genetic Identification Tests.

**Products:** **Forensic Genetics:** Paternity testing, parentage (kinship) analysis and genetic identification (DNA fingerprinting) from any biological traces. Reference Centre in complex kinship testing and complex Forensic sample analysis. Detection of biological fluids (semen, blood and saliva). **Clinical Genetics:** Molecular Diagnostics of more than 250 hereditary diseases. Personalized Genetic Diagnostic Service ( A la carte Diagnostic) to comprise rare diseases. Prenatal Genetic Diagnostic, including the fast aneuploidy screening by QF-PCR, and Pre-implantational Genetic Diagnostic (PGD) to select genetically healthy embryos. **Technology Transfer:** Set up and start up of Molecular Biology turn-key laboratories, focused on human genetic analysis. The designed projects are highly flexible and are adjusted to the petitioner requirements. **Scientific Advisory Services:** Interpretation of expert reports based on DNA evidences in civil legal and penal procedures. Assistance to legal procedures as judicial experts to ratify specialist's reports based on DNA evidences. Theoretical and practical training in Forensic Genetics and Genetic Diagnostic techniques to professionals, private individuals, companies, laboratories and research teams.

**Interest areas for futures colaborations/alliances:** Development of new Molecular Diagnostic techniques. Projects of Forensic Genetics and Genetic Diagnostic training. Development and distribution of new Molecular Diagnostic Kits.

**Contact**

Av. Cerro del Aguila, 9. 1ª  
Planta. Locales 29-31  
San Sebastián de los Reyes  
28700 Madrid

Tel.: + 34 916 592 298  
Fax: + 34 916 592 299  
www.labgenetics.com.es

**Jorge Puente Prieto**  
General Manager  
jorge.puente@labgenetics.com.es



## Who is Who?



### Laboratorios Calier, S.A.

**Sector:** Animal Health Care

**Mission:** Research, development and commercialisation of veterinary products aimed at production animals, together with specialised products aimed at pets and a select range for horses. A company producing raw materials and finished products for the Animal Healthcare market, our activity comprises the research, development, production and commercialisation in 70 countries of generic products, licences and its own know-how, including those lying in the immunological, pharmacological, nutritional and biocide fields. The two vertical biotechnology lines are the extraction and purification of matrix proteins and biological fluids and the production and extraction of heterologous proteins of immunological or pharmaceutical interest. Both lines are oriented towards obtaining hormone and immunological products.

**Products:** Pharmacological pharmaceutical specialities. Immunological pharmaceutical specialities. Animal care, hygiene and handling products. Biocides. Animal food additives.

**Services:** Autovaccines, diagnostics and eradication programmes.

**Aspects linked to biotechnology:** The production of antigens and proteins produced by heterologous systems, in order to obtain products for: Diagnosis, control and prophylaxis. Vaccine products with detectable vaccine antigens. Hormone products for synchronisation of animals coming into heat and ovulation induction.

**Interest areas for futures collaborations/alliances:** General immunology. Animal reproduction. Expression systems of heterologous recombinant proteins

**Contact**

Parque Empresarial Mas Blau II  
C/ Alta Ribagorza 6-8  
El Prat de Llobregat  
08820 Barcelona

Tel.: + 34 935 069 100  
Fax: + 34 935 069 191  
<http://www.calier.es>

**Joan Marca y Puig**  
Marketing Director  
[jmarca@calier.es](mailto:jmarca@calier.es)



### Laboratorios LETI, S.L.

**Sector:** Pharmaceutical Industry

**Mission:** Human Health Care / Therapy. A pharmaceutical laboratory specialised in immunology and preventive medicine, diagnostic products and self-health care.

**Products:** **Allergy:** Diagnoses, allergen extracts for treatment, bacterial treatments, environment control, allergens. **Diagnostics:** Fast and molecular biology diagnostics for infectious diseases. **Personal care:** LETI AT-4, Urea LETI, Sebamed, Letibalm, Letitest, etc. **Vaccines:** Antitetanus; Anti Diphtheria-tetanus-pertussis DTP; LETI polyspecific influenza vaccine. **Veterinary Diagnosis:** LetiQTest.

**Contact**

Gran Via de les Corts Catalanes, 184. 7º 1ª  
Barcelona  
08038 Barcelona

Tel.: + 34 933 945 350  
Fax: + 34 933 329 560  
<http://www.leti.com>

**Gloria Roé**  
Manager of the Diagnosis and  
Vaccines Business  
[groe@leti.com](mailto:groe@leti.com)



Business Members

asebio

### Laboratorios Ovejero, S.A.



**Sector:** Veterinary Pharmaceutical (Animal Health Care)

**Mission:** The development, manufacturing and commercialisation of pharmaceutical and veterinary products.

**Products:** Contract Manufacturing.

**Interest areas for futures collaborations/alliances:** Development of Immunological Products.

**Contact**

Ctra. León Vilecha, 30  
León  
24192 León

Tel.: + 34 902 235 700  
Fax: + 34 987 205 320  
<http://www.labovejero.com>

**Juan Pablo Ovejero**  
General Manager  
[Gerencia@labovejero.es](mailto:Gerencia@labovejero.es)

### Laboratoris Sanifit, S.L.

**Sector:** Biotechnology - Human Health Care - Pharma

**Mission:** Laboratoris Sanifit is a biotechnology company dedicated to the research and development of health products and to transferring this research for the benefit of society.

Sanifit's work focuses on research and development of innovative drugs and products for the treatment and/or prevention of diseases, mainly in the cardiovascular and renal fields.

**Services:**

❖ **SNF-471:** drug in preclinical phase indicated for the prevention of cardiovascular calcifications.

❖ **SNF-571:** drug in preclinical phase indicated for the prevention of calcic renal lithiasis.

❖ Patents granted.

**Interest areas for futures collaborations/alliances:** Drugs and other products in the following areas: Urology, Cardiology, Dermatology, R+D of new drugs.

**Contact**

PARC BIT Ctra. Valldemossa, km 7.4  
Edificio 17 C3  
07121 Palma de Mallorca

Tel.: + 34 871 70 30 62  
Fax: + 34 971 43 99 25  
[www.sanifit.com](http://www.sanifit.com)

**Bernat Isern Amengual**  
Scientific Director  
[laboratoris@sanifit.com](mailto:laboratoris@sanifit.com)



### Laimat Scientific Technical Solutions, S.L.



**Sector:** Biotechnologic: Research and Technologic and Innovative Services for the industry

**Mission:** Providing scientific technical solutions to the industry which develops new highly competitive materials in the pharmaceutical, agro-food, polymers, ceramics and pigments sector.

Integral research and development service which covers the technologic necessities in the sector of these materials.

**Products:** Applied research. I+D+I projects according to the customer. Technology and knowledge management. Analyze and characterizations. Continue formation and legal advice.

We are specialist in the development of projects based in the Physics- Chemistry of the materials in solid and liquid state. Science and nanotechnology particles. Biomaterial solid state. Polymorphism in drugs. Thermodynamic stability. Coating and microencapsulated. Physical-chemical characterizations

**Interest areas for futures collaborations/alliances:** Bio-technologic sector. Pharmaceutical sector, drug discovery, development and processes of new drugs. Agro-food sector. Research and development of new biomaterials: biopolymers, ceramics.

**Contact**

Parque Tecnológico Ciencias de la Salud  
de Granada, Avda. Innovación 1,  
Armillá  
18100 Granada

Tel.: + 34 958 750 951 /  
858 100 141  
Fax: 958 750 951  
<http://www.laimat.com>

**Josefina Pedrajas**  
CEO/ I+D+i Manager  
[fpedrajas@laimat.com](mailto:fpedrajas@laimat.com)





## Who is Who?



## Lipopharma

**Sector:** Biotechnology

**Mission:** Lipopharma is a biotech company aimed at the discovery, design and initial clinical development of new medicines aimed to be used in human pathologies over the basis of the Membrane Lipid Therapy (MLT). Our initial objective is to complete Minerval's Phases I and II of clinical trials for Lung Cancer and Glioma.

**Products:** Minerval, the first molecule to be developed, combines a powerful anti cancer effect with an absence of toxicology or side effects. Lipopharma is also developing a portfolio of new products based on the MLT with potential applications in fields such as neurodegenerative diseases, cardiovascular pathologies or cancer.

**Interest areas for futures colaborations/alliances:** Lipopharma would be interested in collaboration agreements with other companies / research groups specialized in the field of membrane lipids interactions. Lipopharma will also seek alliances with large multinational pharmaceutical companies who can bring in the technical and financial muscle needed to complete last phases of clinical trials, register and eventually commercialize the products worldwide.

**Contact**

Ctra. de Valldemossa Km. 7,4. ParcBIT. Incubadora de Empresas de Base Tecnológica. Edificio 17. 2º piso. Módulo C-8  
07121 Palma de Mallorca

Tel.: + 34 971 439 886  
Fax: + 34 971 910 909  
www.lipopharma.com

**Vicenç Tur**  
CEO  
v.tur@lipopharma.com

## Lonza

## Lonza Biologics Porriño, S.L.

**Sector:** Pharmaceutical

**Mission:** Produce recombinant monoclonal antibodies from mammalian cell culture.

**Products:** Cell culture and recombinant monoclonal antibodies.

**Contact**

La Relba, s/n  
Porriño  
36410 Pontevedra

Tel.: + 34 986 344 060  
Fax: + 34 986 339 209  
http://www.lonza.com

**Jesús Mota Ortega**  
General Manager  
jesus.mota@lonza.com



Business Members

asebio

## Merck Farma y Química S.L.

**Sector:** Pharmaceutical, chemical and biotechnology

**Mission:** Research and development, production and commercialization of products of high quality in the pharmaceutical and chemical sectors. We focus our activities on businesses where we achieve competitive advantages thanks to the innovation of our products, services and systems. We guarantee that our objectives are fulfilled by developing company policies and practices that are responsible with the society and the environment. Merck is present in Spain since the year 1924, having an important presence and a recognized prestige within the pharmaceutical and chemical sectors. Merck has supported its leadership in the pharmaceutical and chemical industry thanks to its constant effort in Research and Development; with an important bet for the clinical R&D in Spain, which has allowed us to reach the qualification of "Muy Buena" at the Plan ProFarma. Likewise, we have a strong commitment with the improvement of the society, for whom we dedicate our products and services. It is this sense, one of Merck's biggest bets in Spain is the Fundación Salud 2000, a foundation that carries out an important social activity for the company.

**Products:** With a portfolio of more than 15.000 products, Merck follows a strategy of diversification focused in two business sectors: Pharmaceutical (Merck Serono and Consumer Health Care) and Chemical (liquid crystals, effect pigments, analytical reagents and test kits, as well as products and services along the entire process chain of the pharmaceutical and biotech industries).

❖ **PHARMA**

- **Merck Serono:** includes innovative leading prescription drugs, for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular and metabolic disorders and psoriasis
- **Consumer Health Care:** includes a wide range of well-known over-the-counter drugs for everyday health.

❖ **CHEMICAL**

- **Liquid Crystals:** leading manufacturer for LCD displays.
- **Pigments:** effect pigments for the automobile industry, plastics, coating; pigments and other substances for the cosmetic industry.
- **Reagents and test kits:** inorganic high quality reagents, organic chemical products, laboratory tests, among others.
- **Life Science Products:** excipients, active principles and other materials for the pharmaceutical and biotech industry.

**Contact**

María de Molina, 40  
Madrid  
28006 Madrid

Tel.: + 34 917 454 400  
Fax: + 34 917 454 431  
http://www.merck.es

**Laura González-Molero**  
President and General Manager  
comunicacion@merck.es



## Who is Who?



## Merck, Sharp & Dohme de España, S.A.

**Sector:** Chemical

**Mission:** The research, development, commercialisation and manufacturing of innovating medicines.

**Products:** Medicines.

**Interest areas for futures colaborations/alliances:**

- ❖ New medicines development in the selected therapeutic area.
- ❖ New therapeutic target research.

**Contact**

Josefa Valcárcel, 38  
Madrid  
28027 Madrid

Tel.: + 34 913 210 678  
Fax: + 34 913 210 859  
<http://www.msd.es>

**Regina Revilla**

Manager for External Relations and  
Communication  
[regina\\_revilla@merck.com](mailto:regina_revilla@merck.com)



## Microbionta

**Sector:** Biotechnology

**Mission:** Application of our technologies of expression and selection of recombinant antibodies in bacteria to the development of new therapeutic antibodies.

**Products:** Technological platform for the selection of antibodies in bacteria by bacterial display.

Specific antibodies as therapeutic agents for inflammation, cancer and infectious diseases.

**Interest areas for futures colaborations/alliances:** New targets involved in inflammation, cancer and infectious diseases, for the selection of new antibodies.

**Contact**

Ronda de Poniente, 4  
Bajo C-D  
Tres Cantos  
28760 Madrid

Tel.: + 34 911 417 150  
Fax: + 34 911 417 151  
[http:// www.microbionta.com](http://www.microbionta.com)

**Myriam de Grado**

[mdegrado@microbionta.com](mailto:mdegrado@microbionta.com)



## Miltenyi Biotec

**Sector:** Health & Cell Therapy

**Mission:** Miltenyi Biotec develops, produces, and markets state-of-the-art products and services for cell separation, cell analysis, cell culture, molecular biology, and clinical research applications.

**Products:** MACS® Technology for Cell Separation. AutoMACS™. CliniMACS®. Microarrays & Bioinformatics. Adsorbers for Therapeutic Apheresis.

**Contact**

Ciudad de la Imagen c/Luis Buñuel nº 2  
Pozuelo de Alarcón  
28223 Madrid

Tel.: 915121290  
Fax: 915121291  
[www.miltenyibiotec.com](http://www.miltenyibiotec.com)

**Ivan Alvarez-Sierra**

Country Manager  
[macs@miltenyibiotec.es](mailto:macs@miltenyibiotec.es)



Business Members

asebio

## Monsanto Agricultura España, S.L.



**Sector:** Agriculture

**Mission:** To attend the world s food needs. To conserve natural resources. To protect the environment. To serve our customers and our shareholders.

**Products:** Monsanto is a group of companies whose activity is aimed at the development and improvement of agriculture and the food sector. For over one hundred years Monsanto has been researching, developing and commercialising services for the farming sector and it has concentrated its aims on providing sustainable agricultural systems, beneficial for farmers all over the world.

Monsanto is committed to developing safe technologies and products that are beneficial for both farmers and consumers.

Our most outstanding products are our herbicides from the Roundup range and the Dekalb brand seeds. For further information on our products go to: <http://monsanto.es/monsantoes/productos.html>.

**Interest areas for futures colaborations/alliances:** Plant Biotechnology. Conservation farming . Biofuels.

**Contact**

Avenida de Burgos, 17  
Madrid  
28035 Madrid

Tel.: + 34 913 432 701  
Fax: + 34 913 432 727  
<http://www.monsanto.es>

**Rosa Moreno**

Communication Manager  
[rosa.m.moreno@monsanto.com](mailto:rosa.m.moreno@monsanto.com)

## Natraceutical Group



**Sector:** Biotechnology

**Mission:** The Natraceutical Group is made up of 7 companies, Natraceutical S.A. based in Spain, Obipektin AG based in Switzerland, Overseal Natural Ingredients Ltd. based in England and Forte Pharma Laboratoires based in Monaco. The Natraceutical Group in 2007 acquired King Food based in Australia and Viscofiber based in Canada. The group has a combined portfolio of over 500 references and specialized products for the foodstuffs, cosmetic and pharmaceutical industries.

**New Launch:** Beta-glucan, under the brand name Viscofiber® provides one of the most convenient and beneficial kinds of fibre. Beta-glucan, a non-starch polysaccharide found in oats and barley, has been the subject of increasing attention with some reports showing the soluble fibre can decrease LDL-C levels

**Our Mission:** To lead the global functional food sector by developing and manufacturing healthy ingredients and services to help our customers achieve optimal performance in the market-place.

**Contact**

Plaza América, 2. 9ª planta  
Valencia  
46004 Valencia

Tel.: + 34 961 920 851  
Fax: + 34 963 353 255  
<http://www.natraceuticalgroup.com>

**Zachary Sniderman**

Marketing Assistant  
[info@natraceuticals.com](mailto:info@natraceuticals.com)





## Who is Who?



## Neocodex, S.L.

### Sector: Biomedical research

**Mission:** NeoCodex is a biomedical and genomic research company focused on understanding the molecular and genetic basis of human disease.

**Products:** Successful in engineering and housing Spain's largest databank of DNA samples, NeoCodex has created a nationwide cooperative of hospital systems, working together to build a fully-annotated network of samples from common disease states present within the uniquely homogenous population of Spain ([www.neocodex.com](http://www.neocodex.com)).

With broad capabilities, spanning the oeuvre of scientific project design, Neocodex has developed an extensive range of available services ranging from full contract completion to supplementary additions and venture execution.

Service potential includes: Patient recruitment and selection Acquisition of necessary biomaterials (i.e. DNA, blood products, etc.) with accompanying clinical data. Project method design using: The candidate gene approach Proprietary methods of genetic validation Conventional case-control, genome-wide searches Patent-protected processes of conducting whole genome associations Marker selection with accompanying technology design DNA genotyping, nucleic acid sequencing, and genomic support services Clinical trial validation Detailed interpretation of results Programs of independent validation Results dissemination packages including: publication, patent submission, IP exploitation and execution.

### Interest areas for futures collaborations/alliances:

HFCC presents clients with a revolutionary new way of conducting whole genome association studies. Used as a prioritization tool, the strategy behind HFCC allows for the use of different, but related, phenotype analysis in the same study, making use of multi-locus analysis instead of the marker-by-marker approach. The technology also makes use of a novel noise-filter that circumvents the problems inherent to multiple testing, thereby reducing the number of patient samples necessary to achieve valid conclusions. The innovation behind the advancement lies in the ability to use smaller sample sets from various disease states of interest, whereby a common patho-physiological state exists.

### Contact

Charles Darwin 6 AccA  
Sevilla  
41092 Sevilla

Tel.: + 34 955 047 618  
Fax: + 34 955 047 325  
[www.neocodex.com](http://www.neocodex.com)

### Rocío Pascual

Assistant  
[rpascual@neocodex.es](mailto:rpascual@neocodex.es)



## Neuron BPh

### Sector: Human health & bioprocess development

**Mission:** NEURON BPh is a private biotech Company focused on the discovery and product development of biomolecules for the prevention and early treatment of neuro-degenerative diseases, mainly Alzheimer disease using our patented technology: hAPPy Mouse, the only transgenic mouse model that contains the genomic form of the human APP gene.

### Products:

- ❖ Development and Optimization of bioprocesses.
- ❖ Screening of molecules with neuroprotective activity.
- ❖ General Toxicity studies.
- ❖ Organ specific toxicity (mainly neurotoxicity).
- ❖ Pharmacokinetic & pharmacodynamic (ADME/tox studies).



Business Members

asebio

**Interest areas for futures collaborations/alliances:** NEURON BPh is always open to incorporate innovative technologies in the fields of the Neurobiology, Microbial Biotechnology and the Natural Products Chemistry.

### Contact

Avda de la Innovación nº 1  
Business Innovation Centre  
Parque Tecnológico de Ciencias de la Salud  
Armillá, 18100 Granada

Tel.: + 34 958 750 598  
Fax: + 34 958 750 459  
<http://www.neuronbp.com>

### Javier Velasco

CEO  
[info@neuronbp.com](mailto:info@neuronbp.com)

## Neuropharma, S.A.



### Sector: Chemical-pharmaceutical-biotechnological

**Mission:** The development of medicines for the treatment of diseases of the CNS.

**Products:** Molecules under research against neurodegenerative diseases, mainly Alzheimer's Disease. Phase I clinical studies have begun with the first molecule in our pipeline.

**Áreas de interés para futuras colaboraciones:** Within our collaborations policy, Neuropharma maintains relations with numerous public and private sector research institutions, to advance in the development of our molecules and for the research into new ones against neurodegenerative diseases.

The company is interested in setting up new collaborations with research centres that will lead to an enhancement of our activities in the field of neurosciences.

### Contact

Avda. de la Industria 52  
Tres Cantos  
28760 Madrid

Tel.: + 34 918 061 130  
Fax: + 34 918 034 660  
<http://www.neuropharma.es>

### Mercedes Rodríguez Barrera

Business Development Manager  
[mrodriguez@neuropharma.es](mailto:mrodriguez@neuropharma.es)

## Neuroscience Technologies, S.L.



### Sector: Biotecnología / Salud Humana

**Mission:** Research on the mechanisms of neuropathic pain. Development of new therapeutic drugs.

**Products:** New drugs for neuropathic pain treatment.

**Services:** Studies on patients with neuropathic pain. Studies on experimental models of axonal hyperexcitability.

**Interest areas for futures collaborations/alliances:** Development of new drugs targeting axonal hyperexcitability. Development of diagnostic devices for neuropathic pain.

### Contact

Parc Científic de Barcelona, Edifici Hélix  
C/ Baldiri Reixac 15-21  
08028 Barcelona

Tel.: + 34 934 020 164  
<http://www.nsc-tec.com>

### Dra. Cristina Quiles

Director  
[cquiles@nsc-tec.com](mailto:cquiles@nsc-tec.com)



## Who is Who?



## Newbiotechnic, S.A.

**Sector:** RD&I, Farming and Agrifoodstuff Biotechnology

**Mission:** To identify, protect and commercialise microbiological and molecular tools with an immediate, practical application in the farming and agrifoodstuffs sector, which are safer for the consumer and more respectful with the environment.

Founded in 1999, NBT is an R&D company in farming and agrifoodstuff biotechnology, with three business areas: 1) Biological control agents 2) Gene technology for improving crops and 3) Molecular diagnostics services. It has genomics and phytopathology laboratories and a pre-industrial production plant and a HR team, including six people with Ph.D s. With a technological portfolio of over 20 patents and a research network of 45 groups at world level, NBT is a pioneer in the development and registration of biofungicides and leader in molecular phytopathology.

**Products:** Biological Control Agents (biofungicides, bioinsecticides). Tools for plant improvement by genetic transformation

**Services:** Genomic and Bio-IT services Phytopathological diagnostics Agrifoodstuff diagnostics Veterinary diagnostics Human genetic diagnostics

**Interest areas for futures collaborations/alliances:** The development of microbiological products for crop protection. Submerged fermentation technology and product recuperation. Co-development/ distribution of natural products for agriculture (microbiological products, plant extracts, organic extracts, etc.). Development of diagnostic genetic tests for farming, aquaculture, veterinary and food product applications. The development of concept tests in plant genetic transformation.

**Contact**

Paseo de Bollullos de la Mitación, 6 - PIBO  
Bollullos de la Mitación  
41110 Sevilla

Tel.: + 34 955 776 710  
Fax: + 34 955 776 711  
www.newbiotechnic.com

**Manuel Rey**  
General Manager  
mrey@nbt.com



## Noray Bioinformatics, S.L.U.

**Sector:** Bio- Information Technology

**Mission:** To serve as a support in information technologies to the biosciences sector, especially in the design, development and implementation of customised software.

**Products:** **Noraymet:** Biopharmacy line for ADME studies. **Cacoready SoftwareTM.** **Noraymet:** ADME. **Noraygen:** Genomics Line. **BITIA:** Correlation of genetic and clinical data on cancer. LIMS platform for genotyping. **Noraygen:** Gene expression. **Norayprot:** Proteomics Line. Proteomics LIMS. **Noraytools:** Line of software products for information management in biosciences. **Fivisoft:** Assisted fertility clinics. **Viogen:** Software for Plant bioprospection and management of bookshops of extracts of microorganisms and plants. **NORAYBANKS:** software for the management and representation of information in Biobancos of cells, tissue, DNA, tumors and microorganisms. **ANIBIO:** Software for management of animal Houses.

**Interest areas for futures collaborations/alliances:** Metabolomics, pharmacogenomics, neurogenomics.

**Contact**

Parque Tecnológico, 801 A  
Derio  
48160 Vizcaya

Tel.: + 34 944 036 998  
Fax: + 34 944 036 999  
http://www.noraybio.com

**Julio Font**  
General Manager  
font@noraybio.com



Business Members

asebio

## Noray Biosciences Group (Noray BG)

**Sector:** Biotechnology

**Mission:**

- ❖ Noray Biosciences Group, founded in December 2006, is a holding Group focussed on Biosciences, situated among the ten first companies of the Spanish Biotechnology sector.
- ❖ The Group is composed by two companies at this moment: Histocell and NorayBio.
- ❖ Its mission is to manage and integrate the companies in the Biosciences sector to enhance their access to the market and their internationalization.
- ❖ Noray BG stands out for its innovation management model, based on efficiency and search of solutions for the real needs of the Biotechnology sector.

**Services:** Noray BG is a holding dedicated to the management of its companies (NorayBio and Histocell, at the moment), in different fields like strategic management, business development, internationalization, financial management and human resources.

**Interest areas for futures collaborations/alliances:** Noray BG's strategy for the near future is based on the continuous growth by means of collaboration agreements with other companies and institutions, development of new innovative products and acquisition or merger with new firms. Everything done with the firm idea of motivating the expansion throughout the European and international market, making the most out of the synergies among the Group companies.

**Contact**

Parque Tecnológico de Bizkaia,  
Edificio 801A, 2ª planta  
Derio - 48160 Bizkaia

Tel.: + 34 944 036 998  
Fax: + 34 944 036 999  
http://www.noraybg.com

**Julio Font**  
President  
font@noraybio.com



## Omnia Molecular, S.L.

**Sector:** Biotechnology

**Mission:** Omnia Molecular Ltd. (Omnia) is a biotech start-up, focused on the development of a new strategy for the discovery of active molecules with applications as antibiotics, antifungals, or anti-parasitary drugs. Omnia owns exclusive rights to patented technology developed at the Barcelona Institute for Research in Biomedicine.

**Products:** Omnia's technology applies a completely new approach to the selection of pharmacological lead compounds, based on a cellular assay that simultaneously screens compounds for several pharmacological parameters, thus accelerating and improving current methods for the discovery of anti-infective drugs. Our screens are directed against a validated target of universal distribution and they can be used to identify lead compounds against any cellular pathogen.

**Interest areas for futures collaborations/alliances:** We are currently focused on the development of new molecules against three human infections: pneumonia caused by Streptococcus pneumoniae, gastric ulcer caused by Helicobacter pylori, and multi-resistant mycosis caused by Aspergillus fumigatus.

**Contact**

C/Baldiri i Reixac, 15-21.  
Edificio Hèlix. Bioincubadora PCB.  
Lab. AB01  
Barcelona  
08028 Barcelona

Tel.: + 34 934 020 158  
Fax: + 34 934 020 157  
http://www.omniamol.com


**Lourdes Saltó**  
Assistant Director  
lsalto@omniamol.com







## Who is Who?



Business Members

asebio



## Operon, S.A.

### Sector: In Vitro Diagnostics

**Mission:** To be international leader in 6 technologies relating to In Vitro Diagnosis: Monoclonal antibodies, recombinant antigens, agglutination latex, immunochromotography, ELISA and Molecular Biology tests.

### Services:

- ❖ Research, development and manufacturing of Monoclonal Antibodies.
- ❖ Research, development and manufacturing of Recombinant Antigens.
- ❖ RD&I and manufacturing of In Vitro Diagnostic kits based on immunological reactions.
- ❖ RD&I and manufacturing of In Vitro Diagnostic kits based on molecular biology

**Interest areas for futures colaborations/alliances:** Industrial production and purification of monoclonal antibodies and recombinant antigens.

Design and large scale production or with own brand of new In Vitro Diagnostic tests.

### Contact

Camino del Plano, 19  
Cuarte de Huerva  
50410 Zaragoza

Tel.: + 34 976 503 597  
Fax: + 34 976 503 531  
<http://www.operon.es>

**Tomás Toribio**  
General Manager  
[Info@operon.es](mailto:Info@operon.es)



## OrphaMed, S.L.

### Sector: Human Health

**Mission:** OrphaMed is dedicated to the research of new indications for existing drugs ( repro-filing ) in less common diseases (commonly known as rare diseases ), in the most simple and direct way, but that had not been possible until now: analyzing by means of a pioneer proprietary technology ( ExviTech ) the effect of thousands of existing drugs directly on a patient's standard biological sample while it is still fresh (24/48 hours).

**Products:** OrphaMed Centers its operations on the following areas of research:

- Hematological Neoplasias (Leukemia and Myelodysplastic Syndrome): More than 100.000 potential new treatments will be evaluated during the next 1.5 years directly in patient samples.
- Combinatorial Cytomic Biomarkers. Development of cytomc biomarkers of chronic stress and depression on clinically characterized human samples.

### Interest areas for futures colaborations/alliances:

- ❖ Hematological Neoplasias (Leukemia and Myelodysplastic Syndrome).
- ❖ Chronic Stress and Depression.

### Contact

C/ Goya 109 1º Izq  
Madrid  
28009 Madrid

Tel.: + 34 914 360 803  
Fax: + 34 983 440 787

**Andrés Ballesteros**  
CEO  
[aballesteros@orphamed.com](mailto:aballesteros@orphamed.com)

## Oryzon Genomics

### Sector: Biotechnology

**Mission:** Oryzon is a biomarker discovery company with a Diagnostic and Therapeutic pipeline focused in Oncology and Neurological disorders. Oryzon's mission is the identification of gene functions and proteins so as to design and develop biotechnological products that improve people's health.

**Services:** The company has an integrated bio-marker discovery and validation platform and develops its own core research program, with an increasing number of projects in selected niches of the biomedicine arena always in partnership with the Academia and Pharmaceutical companies.

**Interest areas for futures colaborations/alliances:** Oryzon has several important strategic alliances with food, biotech and pharmaceutical companies and is looking for industrial pharma and food partners to launch new global projects.

### Contact

Josep Samitier, 1-5  
Barcelona  
08028 Barcelona

Tel.: + 34 934 037 196  
Fax: + 34 934 034 792  
<http://www.oryzon.com>

**Carlos Buesa**  
CEO  
[info@oryzon.com](mailto:info@oryzon.com)

## Palau Pharma

### Sector: Biopharmaceutical

**Mission:** To discover and develop alone or in collaboration with our strategic partners novel, patent-protected pharmaceuticals for the treatment of inflammatory or autoimmune conditions

**Products:** PALAU PHARMA has an attractive pipeline, comprised of projects that are both at the drug discovery stage and in clinical development. Our projects under internal development are: **UR-1505:** Immunomodulator, Phase II. **Dersazaline:** Anti-inflammatory agent , Phase I. **Development Project 1 (DP-1).** Preclinical. **Discovery Project 1 (DD-1).** **Discovery Project 2 (DD-2).** The projects developed by our partners are: **Albaconazole:** Oral and topical antifungal agent (partner: Stiefel Laboratories). **P38 MAP kinase inhibitor:** Anti-inflammatory agent (partner: Organon). **Cimicoxib:** Cyclooxygenase-2 inhibitor for veterinary use (partner not disclosed). **Cimicoxib:** Cyclooxygenase-2 inhibitor for CNS indications (partner: Affectis Pharmaceuticals). **Triflusal-Stents:** Drug eluting coronary stent coated with a polymer containing the drugs triflusal and simvastatin (partner: Iberhospitex)

**Interest areas for futures colaborations/alliances: In-licensing:** We are eager to establish collaborations with companies interested in outlicensing their patent protected New Chemical Entities. We are specially interested in compounds that have reached the late preclinical stage or early Phase I clinical trials. The therapeutic fields of greatest interest to us are diseases of allergic and autoimmune origin, such as psoriasis, atopic dermatitis, rheumatoid arthritis, and inflammatory bowel disease. We will also be pleased to evaluate opportunities in other therapeutic areas. **Out-licensing:** we are building an exciting and attractive pipeline with several projects at various stages of development. Our projects address novel targets. We aim for our molecules to eventually become best-in-class products for the treatment of diseases with unmet medical needs. Out-licensing after having completed at least one Phase II clinical trial (proof-of-concept) forms the core of our business strategy. We are also open to the possibility of establishing partnerships and collaborative agreements at earlier stages of development, as we have successfully done in the past.

### Contact


Pol. Ind. Riera de Caldes  
Avinguda Camí Reial 51-57  
Palau-solità i Plegamans  
08184 Barcelona

Tel.: + 34 938 649 692  
Fax: + 34 938 646 606  
[www.palaupharma.com](http://www.palaupharma.com)

**Lydia Sanmartí Vila**  
Head of Operations  
[lsanmarti@palaupharma.com](mailto:lsanmarti@palaupharma.com)



## Who is Who?



Business Members

asebio



## Pevesa, S.L.

**Sector:** Bioagricultura, Nutraceuticos y alimentación, Fermentaciones industriales, Biofarmacia

**Mission:** Bioagriculture, Nutraceuticals and Foodstuffs, Industrial Fermentations, Biopharmacy.

**Products:** Proteins, peptics, biochemical products.

**Services:**

- ❖ Industrial Biotechnology and Biochemical Engineering.
- ❖ Enzyme and Fermentation Technology.
- ❖ RD&I Laboratories and Pilot plant.

**Interest areas for futures colaborations/alliances:**

- ❖ Contract manufacturing, custom made manufacturing .
- ❖ Product development.
- ❖ Collaboration, research and development agreements for new products.
- ❖ Joint Ventures.
- ❖ Investment in biotech projects.

**Contact**

Polígono Industrial Poliviso  
Avda. de la Industria s/n  
El Viso del Alcor  
41520 Sevilla

Tel.: + 34 955 946 024  
Fax: + 34 955 945 620  
www.pevesa.es

**Iñaki Mielgo**

General Manager and CEO  
imielgo@pevesa.es

Pharmakine

## Pharmakine

**Sector:** Human Health Care

**Mission:** To develop products and services that foster advances in the research, diagnosis and treatment of cancer and metastasis.

**Products:**

Organ-specific primary cultures, tissue arrays, cell-arrays, conditioned media, tumor spheroids.

**Services:**

- ❖ Preclinical evaluation of compounds with anti-tumor, anti-angiogenic or anti-metastatic activity.
- ❖ Oncology diagnosis support services: progression tumor markers, subclinical tumor dissemination and personalized therapy.
- ❖ Specialized histology services.

**Interest areas for futures colaborations/alliances:**

- ❖ Development of novel anti-tumor or anti-metastatic compounds.
- ❖ Development of cell-based assays for preclinical evaluation of drugs.
- ❖ Development of advanced diagnostic systems for the early detection of metastasis.
- ❖ Development of advanced prognostic methods for cancer patients.

**Contact**

Parque Tecnológico de Vizcaya  
Edif. 801-A, 1ª planta  
Derio  
48160 Vizcaya

Tel.: + 34 944 317 037  
Fax: + 34 944 317 039  
http://www.pharmakine.com

**Lorea Mendoza**

CEO  
lmendoza@pharmakine.com

## Pharmamar, S.A.U.

**Sector:** Biopharmaceutical

**Mission:** PharmaMar is a biopharmaceutical company devoted to advance cancer care through the discovery, development and commercialization of innovative marine-derived medicines.

**Products:**

- ❖ **Yondelis®:** European Marketing Authorization (MAA) granted in July 2007 for Soft Tissue Sarcoma. The MAA for the second indication of Yondelis®, ovarian cancer, will be filled to the EMEA in 2008 and Phase II clinical trials are ongoing in Prostate and Breast cancers .
- ❖ **Aplidin®:** Positive Phase II data in heavily pre-treated, relapsed/refractory Multiple Myeloma. Orphan Drug designation by the EMEA and the FDA for Acute Lymphoblastic Leukaemia and Multiple Myeloma.
- ❖ **Kahalalide F:** Promising clinical results from exploratory Phase II trial in severe psoriasis.
- ❖ **Zalypsis y PM02734:** Phase I trials in solid tumors ongoing.

**Interest areas for futures colaborations/alliances:** Our business strategy relies in maintaining a strong pipeline of products in development. For the drugs in our Oncology pipeline, we seek partners for development and commercialization outside of Europe. As well, PharmaMar is interested in licence-in Phase III or commercialize stage products in oncology haematology malignancies, to maximise our specialised commercial organization established in Europe.

**Contact**

Polígono Industrial La Mina  
Avda de los Reyes, 1  
Colmenar Viejo  
28770 Madrid

Tel.: + 34 918 466 000  
Fax: + 34 918 466 001  
http://www.pharmamar.com

**Ana Benavides**

Business Development  
abenavides@pharmamar.com



## Pioneer Hi-Bred Spain, S.L.

**Sector:** Agricultural seeds, Farming

**Mission:** The development, production and commercialisation of agricultural seeds and inoculants for the conservation of animal fodder.

**Products:**

- ❖ Maize, Sorghum, sunflower, cotton, soybean, corn, lucerne, rape seeds.
- ❖ Lactic bacteria inoculants for animal fodder conservation

**Services:** Comprehensive agronomic services of complete advisory service to agricultural users of the plant species marketed.

**Interest areas for futures colaborations/alliances:**

- ❖ The development of varieties of plant species and inoculants for agriculture and stock farming.
- ❖ Development of methods and knowledge concerning stock feeding.
- ❖ Development of varieties of plant species for human nutritional use.
- ❖ Development of varieties and processes for the bio-energy industry.
- ❖ Development of processes for improving and knowing the agricultural crop environment better (soils, waters, efficiency and irrigation methods, abiotic factors, pest control, etc.)

**Contact**

Avda. Reino Unido s/n  
Edificio ADYTEC  
Euroficinas 2ª Planta  
Sevilla  
41012 Sevilla

Tel.: + 34 954 298 300  
Fax: + 34 954 298 340  
http://www.pioneer.com

**Alberto Ojembarrena**

Operations Manager  
Alberto.Ojembarrena@pioneer.com







## Who is Who?



## Proteomika, SL

**Sector:** Biotech. In vitro diagnostic systems based on proteomics.

**Mission:**

- ❖ In vitro diagnostic product development.
- ❖ Non-invasive biomarker discovery.
- ❖ New biomarker validation techniques.
- ❖ To provide the healthcare community with new tools in personalized medicine.

**Products:**

- ❖ IVD Kits in cancer and related pathologies.
- ❖ New serotyping tests and technologies.
- ❖ Therapeutic targets. Proteomic and cytomic services.

**Interest areas for futures colaborations/alliances:**

- ❖ Proteomika actively seeks for industrial and institutional partners in the area of biosciences for the development of in vitro diagnostic products based on non-invasive protein biomarker detection and quantification.
- ❖ Collaborations with biotech companies in the fields of multiplexing platforms and instruments, immunology, microfluidics, and new high throughput biomarker discovery techniques are valued.
- ❖ Collaborations with applied research institutions and pharma companies committed to the development of biotechnological products in the area of interest of Proteomika.

**Contact**

Parque Tecnológico Bizkaia  
Ed. 801B - 2º  
Derio  
48160 Bizkaia

Tel.: + 34 944 064 525  
Fax: + 34 944 064 526  
<http://www.proteomika.com>

**Juan Pedro López Araguás**  
General Manager  
[plaraguas@proteomika.com](mailto:plaraguas@proteomika.com)



## Roche Applied Science

**Sector:** Roche Applied Science is one of the world's leading suppliers of reagents and systems for medical and biotechnological research

**Mission:** "Roche Applied Science provides superior bioanalytical solutions for the life science market", the business areas offers integrated solutions for research applications, including all experimental steps that lead from sample to results

**Products:** With more than 2000 products for:

- Genomics : Instruments and reagents for qPCR , nucleic acid extraction and analysys, pirosequencing and microarrays.
- Proteomics reagents and cellular analysis.
- Raw materials and industrial GMP Grade products, contract manufacturing and customized / dedicated products

**Contact**

Avda Generalitat s/n  
Sant Cugat del Valles  
08174 Barcelona

Tel.: + 34 935 834 000  
Fax: + 34 935 834 062  
[www.roche-as.es](http://www.roche-as.es)  
[www.roche-applied-science.com](http://www.roche-applied-science.com)

**Carlos Manchado-Perdiguero**  
Marketing Manager  
[carlos.manchado-perdiguero@roche.com](mailto:carlos.manchado-perdiguero@roche.com)  
**Neus Diez May**  
Administration  
[neus.diez@roche.com](mailto:neus.diez@roche.com)



Business Members

asebio

## Sabiobbi, S.L.

**Sector:** Biotechnology, Human Health

**Mission:** We are a company dedicated to the marketing, distribution and research of products and services related to human health, beauty and well-being. Relying on the advances of the biotechnology, we have developed 4 diagnostic biochips (by means of the analysis of DNA, through a sample of saliva) that provide the necessary information to establish the genetic profile of a person reflecting the situation and vulnerability opposite to the risks or capacities defined.

**Products:**

- ❖ **AgingChip:** analyzes the polymorphisms linked to diseases associated with aging, metabolic capacity and defense mechanisms, by predicting the risk of suffering from them.
- ❖ **QualityChip:** allows for learning the specific risk of suffering from any expression of vascular disease.
- ❖ **ExecutiveChip:** allows for learning the specific risk of suffering from any expression of vascular disease and some of the diseases associated with oxidative stress (or environmental), including cancer and premature aging, that affect our future quality of life.
- ❖ **SportChip:** allows for analyzing the genes associated with physical capability and metabolic capacity, facilitating the comprehensive assessment of the response potential to exercise.

**Interest areas for futures colaborations/alliances:**

- ❖ Biotechnology.
- ❖ Human Health.

**Contact**

C/ Hermosilla, 28 - 1ºB  
Madrid  
28001 Madrid

Tel.: + 34 913 530 189  
Fax: + 34 913 530 190  
<http://www.sabiobbi.com>

**José Ernesto Olivares**  
Board Member  
[sabiobbi@sabiobbi.com](mailto:sabiobbi@sabiobbi.com)

## Schering-Plough



**Sector:** Pharmaceutycal Indutry

**Mission:** Schering-plough is a global pharmaceutical company with more than 50,000 people in more than 125 countries around the world. The company vision is to earn the trust of doctors, patients and customers as a company that provides them with science-based medicines and services.

**Products:** With the recent combination with Organon in November 2007, the company offers now products in 6 therapeutic areas: cardiovascular disease, central nervous system, immunology and infectious disease, oncology, respiratory and women s health. Moreover, the company has a great pipeline with several products in phase 2 or phase 3 development.

**Interest areas for futures colaborations/alliances:** Schering-plough activity is based in 6 therapeutic areas with interests in: cardiovascular disease, neuroscience, anesthesia, immunology (rheumatoid arthritis, crohn disease, psoriasis), infectious disease (hepatitis c and hiv), oncology, respiratory (asthma and allergy) and women s health (gynecology and fertility).

**Contact**

C/ Cantabria 2.  
Edificio amura  
Alcobendas  
28108 Madrid

Tel.: + 34 915 673 164  
Fax: + 34 915 673 115  
<http://www.schering-plough.es>

**Fernando García Alonso**  
Director Market Access  
[fernando.garcia.alonso@spcorp.com](mailto:fernando.garcia.alonso@spcorp.com)



## Who is Who?



## Seaweed Canarias

### Sector: Marine Biotechnology

**Mission:** To develop and supply our customers with all-round, sustainable, advanced technology solutions, through the industrial application of active principles from seaweeds.

### Products:

- ❖ **Algacan:** a range of ecological biostimulants for agriculture, based on a unique combination of macro and micro seaweeds.
- ❖ **Biocasa:** the first fortificantes for taken care of gardening and of plants of home with ecological certification in Spain and patented product range
- ❖ Functional food compounds enriched with natural ingredients exclusive to seaweeds.
- ❖ Cosmetic products based on active principles from seaweeds such as antioxidants and skin firming products.

### Interest areas for futures colaborations/alliances:

- ❖ Innovation and development of innovating food products that contain nutritional elements and properties exclusive to seaweeds.
- ❖ Development of R&D activities relating to sewage disposal through the application of seaweed s biofiltering properties.
- ❖ Development of innovating products for animal feeds based on the immuno-modulating and prebiotic properties derived from seaweeds.

### Contact

Fuente, 7	Tel.: + 34 928 18 43 55	<b>Sergio Cáceres</b>
Las Palmas de Gran Canaria	Fax: + 34 928 373 506	Institutional Relations Manager
35001 Las Palmas	<a href="http://www.seaweedcanarias.com">http://www.seaweedcanarias.com</a>	<a href="mailto:scaceres@seaweedcanarias.com">scaceres@seaweedcanarias.com</a>



## Sensia, S.L.

### Sector: Biotechnology

**Mission:** Sensia is the first Spanish Initiative to set up a leading company in the instrumentation sector for life science research laboratories and for environment measurement. Sensia develops and commercialises portable, multibiosensor systems, based on technologies developed by the Biosensors Group of the National Microelectronics Centre, belonging to the Higher Council for Scientific Research.

**Products:** **SENSIA<sup>2</sup>-SPR** is an instrument based on Surface Plasmon Resonance (SPR) which enables comparative measurements to be made by incorporating channels. It also includes computer-controlled pumps and microfluid valves for sample injection. The Surface Plasmon resonance is a powerful technology for measuring biomolecular interactions, allowing real-time measurements without having to brand the analytes. The 2-SPR system has a large number of applications; in general all those studies based on biomolecular interactions: biochemical and chemical detection, discovery of medicines, diagnostics, proteomics, genomics, forensic medicine, food analysis, environmental monitoring, etc.

### Interest areas for futures colaborations/alliances:

- ❖ The development of biosensors and their components.
- ❖ The development of new biosensor applications.
- ❖ Basic and clinical research.
- ❖ Diagnostic applications.

### Contact

Pza de la Encina, 10-11.	Tel.: + 34 918 063 089	<b>Juan Sebastián Ruiz</b>
Núcleo 1, 3ª Planta.	Fax: + 34 918 063 090	Institutional Relations Director
Tres Cantos	<a href="http://www.biotherapix.com">http://www.biotherapix.com</a>	<a href="mailto:jsruiz@genetrix.es">jsruiz@genetrix.es</a>
28760 Madrid		



Business Members

asebio

## Sigma Aldrich Química, S.A.

### Sector: Supplies

**Mission:** We are committed to our customers, employees and shareholders success through science, technology and service.

**Products:** Reagents, chemical and biological products, laboratory kits and supplies for scientific life science research, biotechnology and high technology chemistry and for pharmaceutical and chemical development and manufacturing.

**Services:** Customised development and synthesis of chemical and biological products, scale increases.

### Contact

Ronda de Poniente 3, 2ª P	Tel.: + 34 900 101 376	<b>Javier Márquez</b>
Apdo. correos 278	Fax: + 34 900 102 028	General Manager
Tres Cantos - 28760 Madrid	<a href="http://www.sigma-aldrich.com">http://www.sigma-aldrich.com</a>	<a href="mailto:jmarquez@europe.sial.com">jmarquez@europe.sial.com</a>



## Sistemas Genómicos, S.L.

### Sector: Genetic diagnostics and genomic research

**Mission:** The company's main aims are the research, development and commercialisation of analytical applications based on genomics technology. The company s activity is concentrated on the development of analytical methods capable of satisfying the needs of the agrifoodstuff and pharmaceutical industry, hospitals and research centres.

### Services:

- ❖ **Sequencing:** DNA Sequencing Service.
- ❖ **Biomedicine:** Genetic-Molecular Studies, Cytogenetic Studies, Reproductive Genetics Studies.
- ❖ **Agrogenomics:** GMO Analysis Service, Gluten Detection Service, Allergen Detection Service, Fast Pathogen Detection Service, Genetic Authentication of foodstuffs.
- ❖ **Environment Quality:** Rapid Legionella Detection Service
- ❖ **Research:** Agrogenomics, Biomedicine (diagnostics and pharmacogenetics), Genomic Technology, Industrial Biotechnology, Animal Health Care.
- ❖ **Other Business Lines:** Genome Projects, Bio-IT, Transcriptomics, Research Support Services, Traceability.

**Products:** Kit AutentiGen® GMOscreen Kit AutentiGen® Mammals Kit AutentiGen® Salmonella Kit AutentiGen® Birds Kit ExtraGen® Foods Kit ExtraGen® Animal Feeds.

### Interest areas for futures colaborations/alliances:

The company develops and commercialises customised services, products and R&D projects in the following fields:

- ❖ Agrifoodstuffs.
- ❖ Human Health Care.
- ❖ Animal Health Care.
- ❖ Genomic Research.
- ❖ High Technology and Quality Assurance.

### Contact

Parque Tecnológico de Valencia Ronda G. Marconi, 6	Tel.: + 34 902 364 669	<b>Estefanía Perelló</b>
Paterna	Fax: + 34 902 364 670	Marketing department
46980 Valencia	<a href="http://www.sistemasgenomicos.com">http://www.sistemasgenomicos.com</a>	<a href="mailto:estefania.perello@sistemasgenomicos.com">estefania.perello@sistemasgenomicos.com</a>







## Who is Who?



Business Members

asebio



## Soluciones Extractivas Alimentarias, S.L. (SOLUTEX)

**Sector:** Fine Chemicals

**Mission:** Be the world-leading company in the production of ingredients by supercritical CO2 technologies for the pharmaceutical, cosmetic, nutritional, food and beverage industries.

**Products:** EPA (Eicosapentaenoic Acid) until 95%, DHA (Docosahexaenoic Acid) until 85%, SDA (Stearidonic Acid) until 50%, Omega-3 PUFAS until 95%, Lycopene until 50%, Terpeneless Citrus Oils in the desired folding, Sesquiterpeneless Citrus Oils in the desired folding, Terpenes Sesquiterpenes, Magnetic Nanoparticles.

**Interest areas for futures colaborations/alliances:** We look for partners interested in collaborating in clinical studies with products containing our ingredients. We also are interested in partnering with companies with complementary technologies with ours, in order to increase competitiveness or technological development. Of course we are always interested in establishing commercial relationships with first movers in every region/sector.

**Contact**

Parque Empresarial Omega  
Ctra. de Barajas, 24 3º-4º  
Alcobendas - 28109 Madrid

Tel.: + 34 918 060 477  
Fax: + 34 918 060 605  
www.solutex.es

**Fernando G. Santos**

Commercial & Marketing Director  
fgsantos@solutex.es



## Suanfarma, S.A.

**Sector:** Pharmaceutical

**Mission:** To provide manufacturing services for third parties. Co-participation/ investment as industrial partners in the development of biotechnology projects.

**Services:** Consultancy and financing search for biotechnology projects.

**Products:** cGMP manufacturing of proteins in our partner organisation Angel Biotechnology Ltd. (Newcastle, UK): Biopolymers, enzymes, monoclonal antibodies, vaccines, A protein, biogeneric products, etc. cGMP manufacturing of cell cultures: Stem cells, whole cells, etc.

**Interest areas for futures colaborations/alliances:** Biopolymers and bio-remediation. Cell therapies. Therapeutic protein development and manufacturing. Search for investors and partners for biotechnology projects.

**Contact**

Carretera de Fuencarral, 98  
2ª planta  
Alcobendas - 28108 Madrid

Tel.: + 34 915 713 598  
Fax: + 34 915 671 557  
www.suanfarmabiotech.com

**Javier Fernández**

Area Manager  
javierfernandez@suanfarma.com



## Sylentis, S.A.U.

**Sector:** Biotechnology

**Mission:** Biotech and therapeutic applications in interference RNA technology.

**Contact**

José Abascal nº 2  
Madrid  
28003 Madrid

Tel.: + 34 918 234 553  
Fax: + 34 918 466 001  
http://www.sylentis.com

**Ana Isabel Jiménez**

R&D Director  
aijimenez@sylentis.com

## Tetra Therapeutics, S.L.



**Sector:** Human Health

**Contact**

Edificio Central Parque Tecnológico  
Oficina 12- Campus de Tafira  
Las Palmas de Gran Canaria  
Gran Canaria

Tel.: + 34 928 457 305

**A. Carmelo González Rodríguez**

Counselor  
acgles@tetratx.com

## Thrombotargets Europe S.L.



**Sector:** Pharmaceutical Development and High Throughput Screening of libraries of chemical and biotechnological compounds

**Products:**

❖ **Pipeline** (13 products): Antihemorrhagic Program: TT-103MH, TT-111, TT-112, TT-125, TT-126. Anticoagulant Program: TT-105, TT-120 TT-123, TT-124 Antiplatelet Program: TT-113, TT-114 , TT-115. Fibrinolytic Program: TT-116.

❖ **Technological Platforms** (3): BioplatfromScreen (ultra HTS), Recombinant Nanotransporters (NTR) (vehicles for therapeutical agents). Genetic Therapy (NTR containing genetic material).

**Áreas de interés para futuras colaboraciones:**

❖ Our areas of interest are Pharmaceutical Development and HTS

❖ Until that moment we have maid alliances with:

- 6 Spanish Public Centers, 4 of which Universities.
- 3 International Public Centers - 2 in the USA and 1 in Brazil.
- 7 Spanish Private Companies.
- 3 International Private Companies - Russian, Dutch and North American

**Contact**

Lepanto 328 Entlo.  
Barcelona  
08025 Barcelona

Tel.: + 34 934 463 016  
Fax: + 34 934 509 760  
www.thrombotargets.com

**Dr. Ignasi Miquel**

Director de Negocios y Alianzas  
ignasimiquel@thrombotargets.com

Centro Nacional de Biotecnología (CNB)  
Edificio Emergentes, Tercera planta (Lab 30A)  
C/Darwin 3, Campus Cantoblanco  
Madrid  
28049 Madrid

## VidaCord S.L.



**Sector:** Biotechnolgy. Cell Therapy

**Mission:** To process and criopreserve the cord blood that parents entrust VidaCord. To offer their children in the future the possibility to use these cells or their derivatives to treat certain diseases.

**Services:** Obtaining, processing and criopreserving stem cells from blood cord.

**Áreas de interés para futuras colaboraciones:**

- ❖ Cell Therapy.
- ❖ Regenerative Medicine.

**Contact**

Almagro 38, bajo dcha.  
28010 Madrid  
**Laboratorio:** Edificio Zye bajo D  
Tecnoalcalá  
Alcalá de Henares, Madrid

Tel.: + 34 917 026 879  
Fax: + 34 917 026 984  
www.vidacord.es

**Mónica López Barahona**

General Scientific and Technical  
Director  
mlbarahona@vidacord.es



## Who is Who?



### Vircell, S.L.

**Sector:** Human Health Care

**Mission:** To produce quality reagents and to develop innovating products that imply significant advances.

**Products:**

- ❖ **Cell Culture:** cell lines, monoclonal antibodies, means of transporting virus.
- ❖ **IFI:** immuno-fluorescence kits ( single test and multitest).
- ❖ **Brucellacapt:** diagnosis of Brucellosis.
- ❖ **Elisa:** kits for the detection of specific antibodies.

**Contact**

Plaza Domínguez Ortiz 1  
 Polígono Industrial 2 de Octubre  
 Santa Fé  
 18320 Granada

Tel.: + 34 958 441 264  
 Fax: + 34 958 510 712  
<http://www.vircell.com>

**Almudena Rojas**  
 Manager  
[arojas@vircell.com](mailto:arojas@vircell.com)



### Vita Aidelos

**Sector:** Biotechnology

**Mission:** VITA AIDELOS was set up with the objective of creating a positive attitude towards Biotechnology while maintaining scientific rigour. We aim at bridging the gap between the scientific community and society. We collaborate with foundations, museums and scientific sites. We spread scientific advances made in the field of Biotechnology and help society understand science by encouraging critical analysis.

VITA AIDELOS collaborates with the Genome Service: DNA Bank in the University of the Basque Country (UPV/EHU). Thanks to this combination of knowledge and technological experience we have already obtained three Spanish patents and three European ones. New educational material has also been developed: practice kits in Biotechnology to experiment in class or in scientific sites.

**Products:**

- ❖ Patents, *know-how*.
- ❖ Practice Kits in Biotechnology: Molecular Biology and Microbial Biotechnology.
- ❖ Multimedia Products.

**Services:**

- ❖ Spreading and qualification in Biotechnology.
- ❖ Practical consultancy.
- ❖ Taking part in events and activities aimed at spreading Biosciences.

**Interest areas for futures collaborations/alliances:**

- ❖ Commercialization agreements.
- ❖ Taking part in R & D & I projects.
- ❖ Projects aimed at spreading science.

**Contact**

Sangroniz Bidea, 6  
 Sondika  
 48150 Bizkaia

Tel.: + 34 944 069 689  
 Fax: + 34 944 710 241  
<http://www.vita-aidelos.com>


**Melania Rosique**  
 Investigation Manager  
[info@vita-aidelos.com](mailto:info@vita-aidelos.com)



### Vivacell Biotechnology

**Sector:** Biomedicine

**Mission:** VIVACELL BIOTECHNOLOGY ESPAÑA S.L. is a company focussed in Biomedicine and Pharmaceutical Chemistry that investigates in new medical products derived from medicinal plants. The activities of the company are concentrated in the preclinical phase of drug



Business Members

asebio

discovery. We have developed our own platforms of primary screening for plant extracts.

**Products:** Vivacell owns a large collection of plant-derived extracts biologically tested and a library of natural compounds. We have developed CDE-001, an standardised phytoextract with application in colon cancer and inflammatory bowel disease. In addition the company provides specialised in vitro and in vivo models for testing and developing pharmaceutical, nutraceutical and phytopharmaceutical compounds.

**Contact**

Avenida Conde de Valledano nº 15  
 Córdoba  
 14004 Córdoba

Tel.: + 34 957 290 666  
 677 437 513  
[www.vivacellspain.com](http://www.vivacellspain.com)

**Dr. Eduardo Muñoz Blanco**  
 Scientific advisor  
[info@vivacellspain.com](mailto:info@vivacellspain.com)

### Zeltia

**Sector:** Chemical-Biopharmaceutic

**Mission:** Zeltia is an outstanding referente in the improvement of well-being through the fight against cancer, nervous system degenerative diseases and other disease. We have therefore taken up the challenge of pre-empting the future, and this is only possible through constant innovation, with an R&D policy that has positioned us as one of the top eight Spanish companies in R&D investment.

**The companies comprising the Group:**

Pharmamar S.A.U, Neuropharma S.A, Genómica S.A.U, Sylentis S.A.U, Xylazel S.A, Zelnova S.A. y Promax, S.A.

**Services:** The discovery and development of drugs of marine origin, news, scientific publications and management and consolidation the results of the Group.

**Interest areas for futures collaborations/alliances:** Zeltia since its beginnings has collaborated and continues collaborating actively with academic and public centres, with SAME and large businesses of the sector biopharmaceutical and of the chemical, so much national as international sector.

**Contact**

José Abascal, 2  
 Madrid  
 28002 Madrid

Tel.: + 34 914 444 500

**Carmen Eibe**  
 Institucional Relations Manager  
[ceibe@zeltia.com](mailto:ceibe@zeltia.com)

### ZF Biolabs, S.L.

**Sector:** Biotechnology

**Mission:** We are specialized in the use of the Zebrafish (Danio rerio) as an animal model for biomedical and toxicological research.

**Products:** Developmental toxicity assay, acute toxicity assay, organ-specific toxicity assay, gene expression analysis services (RT-PCR), gene knock-down phenotyping. Supply of zebrafish embryo and larvae, custom design systems for maintenance and breeding, inducing spawning technology, feed for adult and fry.

**Interest areas for futures collaborations/alliances:** Toxicity, animal models for human diseases, functional genomic studies, screening of compounds, contract research organization.

**Contact**

Ronda de Valdecarrizo 41º B  
 Tres Cantos  
 Madrid

Tel.: + 34 918 049 020  
 Fax: + 34 918 045 567  
[www.zfbiolabs.com](http://www.zfbiolabs.com)

**Joaquín Guinea López**  
 CEO  
[jguinea@zfbiolabs.com](mailto:jguinea@zfbiolabs.com)







Who is Who?

## Public Members



## Association of Bioenterprises of Valencian Community Region (BIOVAL)

### Sector: Services

**Mission:** · Bioval is a meeting platform for the biotechnological sector in Valencian Community region. Our objective is to promote and support the growth and cooperation of the biotechnological sector in our region · Bioval gathers private companies, research centres, universities, hospitals and other organizations where R+D activities are related to biotechnology.

**Services:** Information to their members: Calendar of courses, conferences, fairs and congresses, Calendar of grants and helps for research works, Organization of Informative Days on topics of interest for their members, Employment, Specific information on technical, legislatives and market aspects, Support the internationalization and the establishments of alliances or agreements of R+D · The promotion of the biotechnical sector of the Valencian Community by means of the participation of the Association in the events related with the sector · The promotion of the associate entities by means of the insert of information on them in our Web and other means of diffusion of the Association · The promotion of this sector by means of an active presence in the media, trade exhibitions and different forums · The foment of the innovation in the sector through the collaboration with the Valencian, national and European local administrations in the development of an appropriate legal and institutional framework · An impulse to technological transfer through strategies in the introduction of biotechnology in user sections and the implantation of biotechnological solutions in traditional sectors · The representation of the this sector interests before Civil Services.

### Contact

Parque Tecnológico. Avenida Benjamín Franklin, 12. Paterna - 46980 Valencia

Tel.: + 34 902 889 990  
Fax: + 34 961 994 220  
www.bioval.org

**María Eugenia Hernández de Pablo**  
Manager  
info@bioval.org



## Aula Dei Foundation Science and Technology Park

### Sector: Research and Transfer of technology within the agrifood an environmental sector

**Mission:** To connect de research centres and the companies. To support and encourage the companies within the agricultural and environmental sector to look for scientific and technological solutions. To transfer the results of the research centres linked to the Park to the production fabric. To spread the researcher's work to enhance its visibility. To arrange and promote the existing technology offer. To detect and give solution to the new technologies needs To encourage the creation and consolidation of innovative companies within the sector.

**Products:** Management of R + D + i contracts between companies and research centres. Advice regarding R & D projects. Business incubator. Innovation and Creation of new technology based firms Programme. Spin off Programme. Cooperation networks for knowledge and technology transference. Transferring and putting the technology on the market. Regional, National and International Financing of R + D + i projects. Training: specialised postgraduate and advanced courses for professionals.

### Interest areas for futures colaborations/alliances:


**Áreas Prioritarias:** Animal Health and Production. Environmental Technology. Forest Resources. Freshwater Resources and irrigation technology. Agricultural Economy. Vegetal health and Nutrition. Food quality and security technology Biotechnology. Genetic Improvement. Agrifood production and container. Bio-mass. Wine technology.

### Contacto

Avenida Montaña 930, Zaragoza 50059 Zaragoza

Tel.: 976 716 976  
Fax: 976 715 220  
www.pctad.com

**Susana Martínez Hernández**  
Aula Dei Foundation Director  
smartinez@aragon.es



Public Members

asebio

## BioBasque, the Basque BioRegion

### Sector: Biosciences

**Mission:** To develop a new business sector related to life sciences, contributing to diversify the current industrial tissue and to maintain competitiveness in an international context.

**Products:** BioBasque is represented by the BioBasque Agency, a one-stop location for biosciences in the Basque Country, and the instrument created to implement the strategy and to co-ordinate the relevant stakeholders.

**Interest areas for futures colaborations/alliances:** BioBasque is interested in establishing contacts with equivalent organisations, and other type of entities, that contribute to support the growth of the biocluster. It is equally interested in contacting companies wishing to establish operations in southern Europe.

### Contact

Parque Tecnológico de Bizkaia, Edificio 801, 2º Derio 48160

Tel.: + 34 946 555 155  
Fax: + 34 946 555 157  
www.biobasque.org

**Dr. María Aguirre**  
BioBasque Agency Manager  
biobasque@spri.es



## Bioregió de Catalunya (BIOCAT)

### Sector: Research and Development

**Mission:** Biocat, the BioRegion of Catalonia, is a public-private organism created with the aim of coordinating companies, public research institutions and the regional Administration in order to boost the biotech sector in Catalonia.

### Products:

- ❖ Biocat strategic lines are the following:
- ❖ Turn Catalonia into an international hub in biotechnology and biomedicine, attractive to companies and researchers.
- ❖ Consolidate Biocat as the one-stop-shop for biotechnology and biomedicine-related activities in Catalonia.
- ❖ Promote the valuation and commercialization of life sciences research in order to help innovations reach the market.
- ❖ Promote the consolidation of the Catalan biotechnology companies.
- ❖ Collaborate to improve the public perception of biotechnology, its benefits and its applications.

### Contact

Pg. Lluís Companys, 23 Barcelona 08010 Barcelona

Tel.: + 34 933 103 330  
Fax: + 34 933 103 360  
www.biocat.cat


### Montse Daban

Communications and External Affairs, Director  
mdaban@biocat.cat





## Who is Who?



Public Members

asebio



## Cartif Foundation -Foods and Chemicals Division- Biotechnology Laboratory

### Sector: R&D activities

**Mission:** The target of the Biotechnology Laboratory of CARTIF Foundation is to incorporate the biotechnology into the companies to increase the innovation in their activities. The main objective consists of the application of biotechnological tools in the agrofood sector in order to develop new production processes as well as to support the existing ones.

### Services:

- ❖ Projects and services in R&D activities:
- ❖ Molecular tools implementation to solve the agrofood sector needs: trazability, food frauds, species identification and guarantee of origins.
- ❖ GMOs and pathogens detection (PCR-RT) as an answer to safety's problems in food, feed and agriculture feedstock.
- ❖ Biotechnological processes to upgrade the agro-industrial residues and to obtain new products.

**Interest areas for futures colaborations/alliances:** New molecular tools development.

Biocatalysis and enzymatic technologies. Immobilization techniques.

Development of submerged and solid state fermentation systems.

### Contact

Parque Tecnológico de Boecillo  
parcela 205  
Boecillo  
47151 Valladolid

Tel.: + 34 983 548 818  
Fax: + 34 983 546 521  
<http://www.cartif.es>

**Dra. M<sup>a</sup> Cristina Ramírez de Lara**  
[criram@cartif.es](mailto:criram@cartif.es)



## Centro Nacional de Investigaciones Oncológicas, CNIO (The National Oncological Research Centre)

### Sector: Human Health Care

**Mission:** Basic and applied research under an integrated approach, fostering the interaction of basic research with of molecular diagnostics programmes and of the discovery of new drugs, all supported by a solid equipment and technical services infrastructure.

### Services:

- ❖ Undertaking research to enable the new, more efficient diagnosis and treatment methods to be obtained for oncological diseases.
- ❖ The transfer of scientific knowledge into clinical practice, so that scientific progress has an effect on our healthcare system as early as possible, and thus on patient welfare.
- ❖ The transfer of technology developed in the CNIO to innovating companies.
- ❖ To set up a new and more effective management system in the European scientific environment.

### Contact

Melchor Fernández Al-  
magro, 3  
Madrid  
28029 Madrid

Tel.: + 34 912 246 900  
Fax: + 34 912 246 980  
[www.cnio.es](http://www.cnio.es)

**José Ignacio Fernández Vera**  
Director of Support to the Investigation  
[vera@cnio.es](mailto:vera@cnio.es)

## Consejo Superior de Investigaciones Científicas, CSIC (The Higher Council for Scientific Research)



### Sector: Scientific research

**Mission:** A public research body, under the auspices of the Spanish Ministry of Science and Technology, that provides research capacity and human resources and materials in the development of new scientific knowledge and the transformation of these into processes and products of social and economic interest.

### Services:

- ❖ To draw up and execute scientific and technological research projects.
- ❖ To draw up and execute collaboration contracts and agreements with companies and with other social agents.
- ❖ To contribute to the analysis and selection of future scientific and technological aims and to advise public administrations on research and technological innovation matters.
- ❖ To foster progress in basic and applied research.
- ❖ To collaborate with the Regional Governments in subscribed research activities.
- ❖ To collaborate with the universities in research and higher education activities.
- ❖ To develop training programmes for researchers and technicians working in the field of science and technology.
- ❖ To collaborate with the National R&D Plan in advisory and management tasks commissioned and with the Regional Governments who request this in the undertaking of their science policies.

### Interest areas for futures colaborations/alliances:

- ❖ Projects in all the biotechnology and biomedicine areas and at the interface between biotechnology and organic chemistry, analytical chemistry, food technology, applied physics, etc.
- ❖ Collaboration with universities, technological centres, industries., etc. to enhance the flow that transforms basic science into social well-being.

### Contact

Serrano 117  
Madrid  
28006 Madrid

Tel.: + 34 915 855 301  
Fax: + 34 915 855 287  
[www.csic.es](http://www.csic.es)

**Prof. José M. Guisán Seijas**  
Manager of the Technology Transfer Office  
[ott@csic.es](mailto:ott@csic.es)

## Fundación Antama (The Antama Foundation)



### Sector: Transgenic Products (Biotechnology)

**Mission:** To increase awareness about biotechnology and its applications in agriculture, the environment and food products.

**Services:** Communication, the organisation of events relating to biotechnology, cabinet for journalist consultations.

### Contact

Travesía de Navaluenga nº 1, 107  
Majadahonda  
28020 Madrid


Tel.: 91 638 98 13  
Fax: 91 634 65 69  
[www.antama.es](http://www.antama.es)

**Elena Fernández Guiral**  
Communication Manager  
**Alfredo López Zamora**  
Assistant  
[fguiral@fundacion-antama.org](mailto:fguiral@fundacion-antama.org)





## Who is Who?



Public Members

asebio



## Fundación Parque Científico de Madrid (PCM)

**Sector:** RD&I

**Mission:** To foster scientific research

**Services:**

- ❖ Business Development: Support for entrepreneurs, Business Creation, Business Incubator, Bioincubator, Access to financing, scientific and university environment.
- ❖ Scientific Services: Genomics, Proteomics, Micro-analysis of materials, Bio-IT, Biotransformations, Animal Health Care.

**Interest areas for futures colaborations/alliances:**

- ❖ The creation of companies with a technological base.
- ❖ Science services to biotech companies.
- ❖ Large scientific facilities.
- ❖ Technical assistance for the creation and management of science and technology parks.

**Contact**

Campus de Cantoblanco  
c/ Einstein, 13 1ª planta (Pab. C)  
Madrid  
28049 Madrid

Tel.: + 34 914 972 400  
Fax: + 34 914 972 401  
www.fpcm.es

**Antonio R. Díaz**  
General Manager  
parque.cientifico@pcm.uam.es



## Granada Health Sciences Technological Park (PTS)

**Sector:** Health - Biotechnology

**Misión:** PTS Granada is a model for the transfer of basic clinical Research and Technology in the field of health and biomedicine which contributes to economic development via:

- The promotion of interdisciplinary research in biomedicine at an international level.
- The protection and transfer of knowledge.
- The consolidation of health sciences business framework based on technology and aimed at clinical practice.
- Being a centre of excellence for healthcar.

**Servicios:**

- ❖ RESEARCH SERVICES: Library, Cell Culture, DNA Sequencing, Genomics and Proteomics, Oligonucleotide Synthesis
- ❖ SERVICES OF TECHNOLOGICAL INNOVATION: Funding of the I+D+i, Transfer of Technology, Industrial Property, Technological Alertness
- ❖ MANAGERIAL SERVICES: Services of EIBTs's creation, Services of incubation, Services of managerial development
- ❖ GENERAL SERVICES: Security, Restaurant, Advisory and Consultation, Marketing and Advertising, Hotels, Healthcare Services, Business Associations, University of Granada, Bioincubator, Technological Innovation Network (RETA), Patents Centre (CITPIA), Innovation Centre, Creation of technology-based companies, Technological trampoline network (CESEAND, RTT), Business Development Support Centre (CADE)

**Interest areas for futures colaborations/alliances:**

Biotechnología y Salud Humana. Biotechnology and Human Health

**Contacto**

C/ Recogidas nº 24  
Portal B Esc A 1ºB  
Granada - 18002 Granada

Tel.: +34 958 535 050  
Fax: +34 958 258 001  
www.ptsggranada.com

Jesús Quero Molina  
Manager  
jqhero@ptsggranada.com

## Gaiker

**Sector:** Human Health Care, Foods, Environment and Services

**Mission:** Gaiker is an innovating centre in technologies relating to plastic materials and composites, the environment, recycling and the evaluation and industrial biotechnology available to companies.

**Services:** Our range of products and services includes the undertaking of R&D projects, technological advisory services and assays and the certification of materials and products. This is complemented by the training we deliver, together with the organisation of communication activities and our technological documentation and surveillance services.

**Interest areas for futures colaborations/alliances:** Gaiker's field of activity is the rendering of Technological Services and Innovation to companies, contributing to their technological development and their competitiveness through the generation, capturing, adaptation and transfer of innovating technologies in industrial biotechnology, plastics and their composites, the treatment and recuperation of contaminated waters and land, as well as industrial waste, recycling, reuse and revaluing of mass consumption waste.

**Contact**

Parque Tecnológico de Bizkaia  
Edif.. 202  
Zamudio - 48170 Vizcaya

Tel.: + 34 946 002 323  
Fax: + 34 946 002 324  
www.gaiker.es

**José María Goenaga**

Director Área Comercial y Marketing  
mark@gaiker.es

## Instituto de Salud Carlos III

**Sector:** Government

**Mission:** A public research body belonging to the Spanish Ministry of Health and Consumption, whose mission is to foster, develop and render technical scientific services in the field of human health care.

**Services:**

- ❖ Research into the different aspects relating to the application of genetic knowledge in diagnosis, therapy, the development of new drugs and epidemiology.
- ❖ The development of innovation in telematics, bio-IT, genomics and proteomics and other new technologies applied to health care.
- ❖ The conservation of international standards and the preparation and conservation of national standards.
- ❖ Awarding aid and subsidies for biomedical research.
- ❖ Drawing up reports about healthcare technologies and services aimed at consolidating decision-making at the different levels of the National Healthcare System.

**Interest areas for futures colaborations/alliances:**

- ❖ Molecular Diagnosis.
- ❖ Telematics and Bio-IT.
- ❖ Proteomics and genomics.
- ❖ Healthcare technologies.

**Contact**

Sinesio Delgado, 6  
Madrid  
28029 Madrid

Tel.: + 34 918 222 000  
Fax: + 34 913 877 830  
www.isciii.es

**Julia Medrano Chivite**

OTRI SG Service Chief for international Research  
Programmes and Institutional Relations  
otri@isciii.es



## Who is Who?



## La Rioja Government. Directorate-General for Innovation

### Sector: Regional administration

#### Mission:

- ❖ R+D and Innovation Policies Design.
- ❖ Communication of the relevance of the R+D and Innovation issues.
- ❖ Regional coordination of those activities.
- ❖ Push up of the technology transfer.
- ❖ Facilitate the growing up of new innovative companies.
- ❖ Enlarge the research activity in La Rioja.
- ❖ Be in the European R+D and Innovation Network.
- ❖ Focus the local companies to the new technologies to improve their competitiveness.

#### Services:

- ❖ New Third R+D and Innovation Regional Plan 2.008-2.011.
- ❖ New Regional Law for R+D and Innovation.
- ❖ Technology Surveillance and Prospective.
- ❖ Support our companies to participate in R+D and Innovation projects.
- ❖ Develop activities to transfer the biotechnological solutions to traditional companies.
- ❖ Helping companies to reach funds for biotechnological projects.
- ❖ Coordination of the Technologies Centres in La Rioja.
- ❖ Communicate to a public of all ages the relevance of the biotechnology.

**Interest areas for futures collaborations/alliances:** All related to the above mentioned objectives.

#### Contact

Centro Tecnológico de La Rioja  
Avda. de Zaragoza, s/n  
Logroño  
26071 La Rioja

Tel.: + 34 941 291 684  
Fax: + 34 941 291 934  
www.larioja.org

**Javier Ureña Larragán**  
Director-General for Innovation  
dg.innovacion@larioja.org



## NEIKER - Instituto Vasco de Investigación y Desarrollo Agrario

### Sector: Agricultural and Environmental Research

**Mission:** Neiker is a Technological Center whose mission is performing research in the field of agricultural, animal, forestry and environmental sciences, being life sciences and biotechnology the base for all the previous research, contributing and collaborating to the development of the enterprise network of the former sectors.

#### Services:

- ❖ R+D+i projects .
- ❖ Analytical and advising services (E+C).
- ❖ Technological services, assistance and technical advising, education and training, technological alert and prospective.
- ❖ Technology transfer and support to the entrepreneurship.

#### Contact

Parque Tecnológico de Bizkaia  
Parcela 812. C/Berreaga, 1  
48160 Derio (Bizkaia)

Tel.: + 34 944 034 300  
Fax: + 34 944 034 310  
www.neiker.net

**Susana Hormilla**  
Commercial Director  
shormilla@neiker.net



Public Members

asebio

## Parc Científic de Barcelona (PCB) (Barcelona Science Park)

### Sector: Biomedicina

**Mission:** The Parc Científic de Barcelona (PCB) is a pioneering innovation system created 10 years ago by the University of Barcelona.

The mission of the PCB is to boost quality research, to foster knowledge and technology transfer and to facilitate the creation of new, technology-based companies.

**Services:** It houses over 46 companies, three large research centers and the PCB-Santander Bioincubator, which undertake their activity in the emerging areas of chemical, pharmaceutical and biotechnology research as well as nano-bioengineering.

The PCB's hosts have access to a large technology offer ([www.pcb.ub.es/servicios](http://www.pcb.ub.es/servicios)), including:

- Technology Platforms.
- Scientific and Technical Services SCT-UB.
- Scientific Services-PCB.

**Interest areas for futures collaborations/alliances:** The PCB collaborates and seeks alliances with researchers, entrepreneurs, institutions and companies interested in making contributions to the fields of biomedicine, nanobioengineering, biotechnology, agro-food and other related areas. They may devote their efforts to basic research, to product development or to the creation of technology-based innovative companies.

#### Contact

Campus Diagonal  
Universitat de Barcelona  
Baldri Reixac, 10  
08028 BARCELONA

Tel.: + 34 93 402 90 60  
Fax: + 34 93 402 90 63  
[www.pcb.ub.es](http://www.pcb.ub.es)

**Sonia Martínez Arca**  
Science Manager  
[smartinez@pcb.ub.es](mailto:smartinez@pcb.ub.es)





## Who is Who?



## UAB. Parc de Recerca. Oficina de innovación, traducción y creación de empresas

**Sector:** People with an entrepreneurial spirit who form part of the UAB: Lecturers, researchers, students, alumni, administration and services staff and other people linked to the UAB.

**Mission:**

- ❖ To foster the entrepreneurial spirit within the UAB. .
- ❖ To foster the creation of an entrepreneurial centre in order to attract innovating projects from entrepreneurs within the sphere of the UAB in their most embryonic stages and to support them during their creation period until they become competitive companies going on to form part of Catalonia's business fabric.

**Services:**

- ❖ To support the execution of business plans from UAB entrepreneurs. Personal accompaniment and coaching. Specific training in the area of entrepreneurship. Seeking financing for business initiatives. To support project viability during the established creation period. Consolidation of human capital and setting up of strategic alliances. Management and co-ordination of UAB company nurseries:
- ❖ Masía Can Fatjó PTV, UAB Company Nursery.
- ❖ Biotechnology and Biomedicine to Biocampus Company Nursery VE3B).
- ❖ Partner Centre Nurseries.
- ❖ National Microelectronics Centre.
- ❖ Computer Viewing Centre.
- ❖ Artificial Intelligence Research Institute.
- ❖ Mates, an economic interest group based on research into materials and gases.
- ❖ Internationalisation and networking.

**Contact**

Campus de la UAB - Edificio A  
Bellaterra (Cerdanyola del Vallés)  
08193 Barcelona

Tel.: + 34 935 814 235  
Fax: + 34 935 812 023  
www.uab.es

**Sonia González**

Business Creation and Innovation  
Office Manager  
sgonzalezg@uab.cat



## Universidad de Navarra

**Sector:** Higher Education, research and health care

**Mission:** Higher education, basic and applied research and specialised medical attention.

**Contact**

Campus Universitario s/n  
Pamplona  
31080 Navarra

Tel.: + 34 948 425 600  
Fax: + 34 948 425 619  
www.unav.es

**José Manuel Zumaquero**

Legal Representative

**María Font**

Person for Scientific Contacts  
jmzumaquero@unav.es



Public Members

asebio

## Veterindustria

**Sector:** Animal Health Care

**Mission:** To defend the collective interests of the associated companies that manufacture and/or commercialise the following products and services in Spain: Veterinary medicines, animal healthcare and nutritional products and additives for animal nutrition, through its different co-ordination, advisory and communication services, to thus promote all the aspects of the Animal Healthcare and Nutrition Industry, benefiting both the sector and society in general.

**Contact**

Fernanflor 8, 1-A  
Madrid  
28014 Madrid

Tel.: + 34 91 369 21 34  
Fax: + 34 91 369 39 67  
www.veterindustria.com

**Santiago de Andrés**

Director General  
veterindustria@veterindustria.com



## Zona Especial Canaria (ZEC)

**Sector:** Public Administration. Consortium between the Ministry of Economic Affairs and Finance and the Canary Islands Government.

**Mission:** To attract investments to the Canary Islands and create employment with the aim of diversifying the production base of the Islands. Biotechnology is a strategic area for the ZEC.

**Services:** The Canary Islands Special Zone is a low tax zone. The main attraction is the corporate income tax at the rate of 4% as opposed to the average Spanish rate of 30%.

**Interest areas for futures colaborations/alliances:**

Companies interested in being located or opening subsidiaries in the Canary Islands.

**Contact**

Avenida José Antonio, 3 5ª planta  
(Edificio MAPFRE)  
Santa Cruz de Tenerife  
38003 Santa Cruz de Tenerife

Tel.: + 34 922 298 010  
Fax: + 34 922 278 063  
www.zec.org

**José Cerezo**

Director of External Relations  
jmcerezo@zec.org



